0001437749-23-011640 | 10-K/A | XBRL Viewer

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

	December 31, 2021
	As Previously Reported			Adjustment		As Restated
Assets
Current assets
Cash and cash equivalents	$	33,206,712		$	—	$	33,206,712
Restricted cash		6,338,306			—		6,338,306
Accounts receivable, net		8,010,708			—		8,010,708
Prepaid expenses		864,513			1,771,711		2,636,224
Total current assets		48,420,239			1,771,711		50,191,950
Operating lease right-of-use assets		2,615,204			—		2,615,204
Financing lease right-of-use assets		4,019,322			—		4,019,322
Equipment, net		24,314,455			—		24,314,455
Total assets	$	79,369,220		$	1,771,711	$	81,140,931
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$	4,458,525		$	—	$	4,458,525
Forward share purchase liability		6,338,306			—		6,338,306
Notes payable – current portion		25,013			1,771,711		1,796,724
Operating lease liabilities, current portion		1,142,413			—		1,142,413
Finance lease liabilities, current portion		161,050			—		161,050
Due to related party		2,367			—		2,367
Deferred grant income		100,000			—		100,000
Accrued expenses and other current liabilities		12,455,888			—		12,455,888
Total current liabilities		24,683,562			1,771,711		26,455,273
Operating lease liabilities, noncurrent		1,653,185			—		1,653,185
Finance lease liabilities, noncurrent		3,762,430			—		3,762,430
Warrant liabilities		10,720,130			—		10,720,130
Notes payable, noncurrent		—			—		—
Total liabilities		40,819,307			1,771,711		42,591,018
Commitments and contingencies (Note 17)
Stockholders’ equity
Preferred stock; $0.0001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding at December 31, 2021 and 2020		—			—		—
Common stock; $0.0001 par value; 490,000,000 shares authorized at December 31, 2021 and 2020; 43,487,279 and 25,973,406 shares issued and outstanding at December 31, 2021 and 2020, respectively		4,349			—		4,349
Additional paid-in capital		67,674,515			—		67,674,515
Accumulated deficit		(29,128,951	)		—		(29,128,951	)
Total stockholders’ equity		38,549,913			—		38,549,913
Total liabilities and stockholders’ equity	$	79,369,220		$	1,771,711	$	81,140,931

	Year Ended December 31, 2021
	As Previously Reported			Adjustment			As Restated
Cash flows from operating activities:
Net (loss) income	$	(17,144,531	)	$	—		$	(17,144,531	)
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Gain on debt extinguishment of Paycheck Protection Program SBA Loan		(665,596	)		—			(665,596	)
Depreciation and amortization		1,488,614			—			1,488,614
Amortization of right-of-use assets		164,983			—			164,983
Stock-based compensation expense		2,314,682			—			2,314,682
Gain on sale of equipment		(5,488	)		—			(5,488	)
Changes in fair value of warrant liabilities		4,151,068			—			4,151,068
Changes in operating assets and liabilities
Accounts receivable		12,558,790			—			12,558,790
Prepaid expenses		513,363			(1,771,711	)		(1,258,348	)
Right-of-use assets – operating lease		(63,626	)		—			(63,626	)
Accounts payable		(2,935,521	)		—			(2,935,521	)
Deferred income		—			—			—
Due to related party		(2,727	)		—			(2,727	)
Accrued expense and other current liabilities		3,384,573			—			3,384,573
Net cash provided by operating activities		3,758,584			(1,771,711	)		1,986,873

Cash flows from investing activities:
Proceeds from the sale of equipment		—			—			—
Purchases of equipment		(10,943,657	)		—			(10,943,657	)
Net cash used in investing activities		(10,943,657	)		—			(10,943,657	)

Cash flows from financing activities:
Proceeds from Business Combination, net of transaction costs		34,340,225			—			34,340,225
Proceeds from issuance of notes payable		—			2,840,619			2,840,619
Payments of notes payable		(24,143	)		(1,068,908	)		(1,093,051	)
Principal payments on finance leases		(203,124	)		—			(203,124	)
Proceeds from exercise of stock options		6,750			—			6,750
Net cash provided by financing activities		34,119,708			1,771,711			35,891,419

Net increase in cash, cash equivalents, and restricted cash		26,934,635			—			26,934,635
Cash, cash equivalents, and restricted cash
Beginning of year		12,610,383			—			12,610,383
End of year	$	39,545,018		$	—		$	39,545,018

Schedule of Cash and Cash Equivalents [Table Text Block]

	*December 31, 2021*		*December 31, 2020*
Cash and cash equivalents	$	33,206,712	$	12,610,383
Restricted cash		6,338,306		—
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$	39,545,018	$	12,610,383

Schedule of Property, Plant, and Equipment, Useful Life [Table Text Block]

(in years)
Animal facility equipment		7
Laboratory equipment		7
Leasehold improvements	Shorter of asset life or lease term
Office furniture & equipment		5
Vehicles		5

Note 13 - Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	*Total*		*Quoted Prices In Active Markets (Level 1)*		*Significant Other Observable Inputs (Level 2)*		*Significant Other Unobservable Inputs (Level 3)*
Liabilities:
Public Warrant liability	$	10,292,500	$	10,292,500	$	—	$	—
Private Placement Warrant liability	$	427,630		—		—		427,630
Total	$	10,720,130	$	10,292,500	$	—	$	427,630

Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table Text Block]

	*2021*
Balance, December 31, 2020	$	—
Initial measurement on the Closing Date		244,062
Change in fair value of Private Placement Warrant liability		183,568
Balance, December 31, 2021	$	427,630

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

	*(Initial Measurement) October 22, 2021*			*December 31, 2021*
Risk-free interest rate		1.22	%		1.24	%
Expected term remaining (years)		5.00			4.81
Implied volatility		25.5	%		43.0	%
Closing common stock price on the measurement date	$	8.44		$	7.81

Note 4 - Reverse Recapitalization and Business Combination (Details Textual) - USD ($)	Oct. 22, 2021	Oct. 12, 2021	Dec. 31, 2021	Dec. 31, 2020
Common Stock, Par or Stated Value Per Share (in dollars per share)			$ 0.0001	$ 0.0001
Security Purchased under Agreement to Resell, Subject to Master Netting Arrangement, Liability Offset	$ 13,098,599		$ 6,338,306
Forward Share Purchase Agreement [Member]
Sale of Stock, Number of Shares Issued in Transaction (in shares)		1,390,000
Sale of Stock, Price Per Share (in dollars per share)		$ 10.10
Common Stock Shares Held by Subsidiary (in shares)		1,296,891
First Earnout [Member]
Percentage of Earn Out Shares to be Released	25.00%
Period to Issue Earn Out Shares (Year)	5 years
Volume Weighted Average Price Threshold (in dollars per share)	$ 15.00
Shareholders Equity Volume Weighted Average Price Threshold Trading Days (Day)	20 days
Shareholders Equity Volume Weighted Average Price Threshold Consecutive Trading Days (Day)	30 days
Second Earnouts [Member]
Percentage of Earn Out Shares to be Released	25.00%
Period to Issue Earn Out Shares (Year)	5 years
Volume Weighted Average Price Threshold (in dollars per share)	$ 20.00
Shareholders Equity Volume Weighted Average Price Threshold Trading Days (Day)	20 days
Shareholders Equity Volume Weighted Average Price Threshold Consecutive Trading Days (Day)	30 days
Third Earnouts [Member]
Percentage of Earn Out Shares to be Released	25.00%
Period to Issue Earn Out Shares (Year)	5 years
Volume Weighted Average Price Threshold (in dollars per share)	$ 25.00
Shareholders Equity Volume Weighted Average Price Threshold Trading Days (Day)	20 days
Shareholders Equity Volume Weighted Average Price Threshold Consecutive Trading Days (Day)	30 days
Fourth Earnouts [Member]
Percentage of Earn Out Shares to be Released	25.00%
Period to Issue Earn Out Shares (Year)	5 years
Volume Weighted Average Price Threshold (in dollars per share)	$ 30.00
Shareholders Equity Volume Weighted Average Price Threshold Trading Days (Day)	20 days
Shareholders Equity Volume Weighted Average Price Threshold Consecutive Trading Days (Day)	30 days
Big Cypress Acquisition Corp [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	36,465,343
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001
Volume Weighted Average Price Threshold Period For Earn Out Shares (Year)	5 years
Sale of Stock, Number of Shares Issued in Transaction (in shares)	36,465,343
Common Stock [Member] \| Big Cypress Acquisition Corp [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	36,465,343
Volume Weighted Average Price Threshold Period For Earn Out Shares (Year)	5 years
Contingent Right to Receive Pro Rate Portion of Earn Out Shares (in shares)	12,000,000
Earn Out Shares, Contingently Issuable (in shares)	1,508,063
Contingent Right, Earn Out Shares, Outstanding (in shares)	10,491,937
Contingent Consideration Classified as Equity, Fair Value Disclosure	$ 101,300,000

Note 2 - Summary of Significant Accounting Policies - Estimated Useful Life (Details)	12 Months Ended
	Dec. 31, 2021
Estimated useful life (Year)	3 years
Animal Facility Equipment [Member]
Estimated useful life (Year)	7 years
Laboratory Equipment [Member]
Estimated useful life (Year)	7 years
Office Equipment [Member]
Estimated useful life (Year)	5 years
Vehicles [Member]
Estimated useful life (Year)	5 years

Note 14 - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Net operating loss carryforwards	$ 5,078,429	$ 2,659,082
Stock-based compensation	1,156,235	600,592
Vacation accrual	99,300	84,553
Lease liabilities	623,286	727,587
Other accrued expenses	1,119,721	0
Start-up costs	297,136	0
Total deferred tax assets	8,374,107	4,071,814
Less valuation allowance	(5,300,689)	(2,320,958)
Total deferred tax assets after valuation allowance	3,073,418	1,750,856
Operating lease right-of-use asset	551,547	641,135
Depreciation and amortization	2,521,871	1,109,721
Total deferred tax liabilities	3,073,418	1,750,856
Net deferred tax asset (liability)	$ 0	$ 0

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2021	Mar. 25, 2022	Jun. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0001833214
Entity Registrant Name	SAB Biotherapeutics, Inc.
Amendment Flag	true
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2021
Document Type	10-K/A
Document Annual Report	true
Document Period End Date	Dec. 31, 2021
Document Transition Report	false
Entity File Number	001-39871
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-3899721
Entity Address, Address Line One	2100 East 54th Street North
Entity Address, City or Town	Sioux Falls
Entity Address, State or Province	SD
Entity Address, Postal Zip Code	57104
City Area Code	605
Local Phone Number	679-6980
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 114,540,000
Entity Common Stock, Shares Outstanding		42,955,121
Amendment Description	SAB Biotherapeutics, Inc., a Delaware corporation (“SAB” or the “Company”, “we”, “our” or “us”) is filing this Amendment No. 1 to the Annual Report on Form 10-K (the “Form 10-K/A” or “Amended Annual Report”) to amend our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities Exchange Commission (the “SEC”) on March 29, 2022 (the “Original Form 10-K”), to restate the financial statements as of and for the year ended December 31, 2021. In March 2023, the Audit Committee of the Company’s Board of Directors and the Company’s management concluded that the Company’s Original Form 10-K should no longer be relied upon as a result of the following accounting errors: ● The Company concluded that it did not correctly account for a financed insurance premium whereby a third-party lender prepaid the Company's annual insurance premiums to our insurance companies in exchange for a short-term interest bearing note (the “Insurance Financing Agreement”). The Company previously recognized, on its consolidated balance sheet, a current prepaid asset for the amount paid by the Company under the Insurance Financing Agreement in excess of the total amortized value of the prepaid insurance policy. The Company reassessed its accounting for the Insurance Financing Agreement and determined that the Insurance Financing Agreement should be classified as a current note payable with the full amount of the insurance premium recognized as current prepaid asset at the time the Company entered into the Insurance Financing Agreement. ● The Company concluded that the Insurance Financing Agreement and corresponding payment to the third-party lender constitutes a constructive receipt and disbursement of cash. As a result, the Company determined the cash flows from financing activities contained within the Prior Year Financial Statements is understated—this error is accompanied by a corresponding overstatement in cash flows from operating activities due to an understated prepaid asset. ● Similar to the above assessment, the Company concluded that the cash payments to the third-party lender should be presented within cash flows from financing activities. As a result, the Company determined the cash flows from financing activities contained within the Prior Period Interim Financial Statements are overstated—this error is accompanied by a corresponding understatement in cash flows from operating activities due to the derecognition of the previously unrecognized prepaid asset. Accordingly, the Company is filing this 10-K/A to amend Part II, Item 7 and to restate Part II, Item 8 and Part IV, Item 15 of the Original Form 10-K. In addition, pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Form 10-K/A also contains new certifications by the principal executive officer and the principal financial officer in Exhibits 31.1, 31.2, 32.1 and 32.2 as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002. This Form 10-K/A also contains an updated consent of the Company’s independent registered public accounting firm, included as Exhibit 23.1. Except as set forth in this Form 10-K/A, this Form 10-K/A does not amend or otherwise update any other information in the Original Form 10-K. Other than the information specifically amended and restated herein, this Form 10-K/A does not reflect events occurring after March 29, 2022, the date of the Original Form 10-K, or modify or update those disclosures that may have been affected by subsequent events. Accordingly, this Form 10- K/A should be read in conjunction with the Original Form 10-K and with our filings with the SEC after the Original Form 10-K.
Auditor Name	Mayer Hoffman McCann P.C.
Auditor Location	San Diego, California
Auditor Firm ID	199
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
Trading Symbol	SABSW
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common stock, $0.0001 par value per share
Trading Symbol	SABS
Security Exchange Name	NASDAQ

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Revenue
Total revenue	$ 60,876,078	$ 55,237,759
Operating expenses
Research and development	57,183,589	27,908,659
General and administrative	17,085,692	6,772,303
Total operating expenses	74,269,281	34,680,962
(Loss) income from operations	(13,393,203)	20,556,797
Changes in fair value of warrant liabilities	(4,151,068)	0
Gain on debt extinguishment of Paycheck Protection Program SBA Loan	665,596	0
Other income	5,488	3,996
Interest expense	(294,459)	(469,151)
Interest income	23,115	26,131
Net (loss) income	$ (17,144,531)	$ 20,117,773
Earnings (loss) per common share attributable to the Company’s shareholders
Basic (loss) earnings per common share (in dollars per share)	$ (0.63)	$ 0.79
Diluted (loss) earnings per common share (in dollars per share)	$ (0.63)	$ 0.74
Weighted-average common shares outstanding – basic (in shares)	27,339,180	25,391,084
Weighted-average common shares outstanding – diluted (in shares)	27,339,180	27,011,482
Grant [Member]
Revenue
Total revenue	$ 60,876,078	$ 55,237,759

Note 14 - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Net (loss) income before tax	$ (17,144,531)	$ 20,117,773
Federal income tax at statutory rate	$ (3,600,352)	$ 4,224,732
Federal income tax at statutory rate, percentage	21.00%	21.00%
State income tax	$ (9,849)	$ 0
State income tax, percentage	0.06%	0.00%
Permanent items	$ 1,029,874	$ 918
Permanent items, percentage	(6.01%)	(0.01%)
Valuation allowance	$ 2,679,238	$ (4,225,651)
Valuation allowance, percentage	(15.63%)	(20.99%)
Other	$ (98,911)	$ 1
Other, percentage	0.58%	0.00%

Note 7 - Equipment - Property, Plant, and Equipment (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Less: accumulated depreciation and amortization	$ 3,220,016	$ 1,767,186
Property, plant and equipment net	24,314,455	14,845,470
Laboratory Equipment [Member]
Property, plant, and equipment, gross	7,431,988	5,205,346
Animal Facility [Member]
Property, plant, and equipment, gross	8,357,667	3,371,125
Animal Facility Equipment [Member]
Property, plant, and equipment, gross	1,253,879	1,003,629
Construction in Progress [Member]
Property, plant, and equipment, gross	4,608,778	6,729,673
Leasehold Improvements [Member]
Property, plant, and equipment, gross	5,700,364	185,971
Vehicles [Member]
Property, plant, and equipment, gross	135,593	96,693
Office Equipment [Member]
Property, plant, and equipment, gross	$ 46,202	$ 20,219

Note 12 - Stock Option Plans - Schedule of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Balance, outstanding (in shares)	4,101,943	3,139,855
Balance, weighted average fair value (in dollars per share)	$ 1.43	$ 0.82
Balance, weighted average exercise price (in dollars per share)	$ 1.30	$ 0.88
Granted, options (in shares)	1,346,947	962,088
Granted, weighted average fair value (in dollars per share)	$ 5.36	$ 3.44
Granted, weighted average exercise price (in dollars per share)	$ 5.81	$ 2.69
Forfeited, options (in shares)	328,718	0
Forfeited, weighted average fair value (in dollars per share)	$ 2.17
Forfeited, weighted average exercise price (in dollars per share)	$ 2.06
Exercised, options (in shares)	12,500	0
Exercised, weighted average fair value (in dollars per share)	$ 0.39
Exercised, weighted average exercise price (in dollars per share)	$ 0.54
Balance, outstanding (in shares)	5,107,672	4,101,943
Balance, December 31, 2020 (in dollars per share)	$ 2.30	$ 1.43
Balance, weighted average exercise price (in dollars per share)	$ 2.44	$ 1.30
Unvested options (in shares)	1,382,715
Unvested, weighted average fair value (in dollars per share)	$ 5.41
Unvested, weighted average exercise price (in dollars per share)	$ 5.92
Vested and exercisable options (in shares)	3,724,957	3,202,354
Vested and exercisable, weighted average fair value (in dollars per share)	$ 1.14
Vested and exercisable, weighted average exercise price (in dollars per share)	$ 1.16

Note 4 - Reverse Recapitalization and Business Combination (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Business Combination Reconciliations [Table Text Block]

	*Recapitalization*
Cash - BCYP trust and cash, net of redemptions	$	22,535,723
Plus: restricted cash - Forward Share Purchase Agreement		13,098,599
Less: cash transaction costs allocated to the Company's equity		(1,294,097	)
Total	$	34,340,225

	*Recapitalization*
Cash - BCYP trust and cash, net of redemptions	$	22,535,723
Plus: restricted cash - Forward Share Purchase Agreement		13,098,599
Less: non-cash net working capital assumed from BCYP		(5,067,682	)
Less: forward share purchase liability assumed from BCYP		(13,098,599	)
Less: fair value of redeemable warrants		(6,569,062	)
Less: transaction costs allocated to the Company's equity		(3,294,096	)
Total	$	7,604,883

Schedule of Common Stock Outstanding Roll Forward [Table Text Block]

	*Shares*
Common stock, reedeemable and outstanding prior to Business Combination		11,500,000
Less: redemption of BCYP shares		(8,030,289	)
Common stock of BCYP		3,469,711
BCYP Founder and private shares		3,292,200
Shares issued for services		247,525
Total BCYP shares		7,009,436
SAB Biotherapeutics, Inc and subsidiaries shareholders		36,465,343
Total shares of common stock immediately after Business Combination		43,474,779

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

Assets Acquired
BCYP trust and cash, net of redemptions	$	22,535,723
Restricted cash - Forward Share Purchase Agreement		13,098,599
Other assets		102,742
Assets acquired	$	35,737,064
Liabilities Assumed
Forward share purchase liability	$	13,098,599
Fair value of redeemable warrants		6,569,062
Other liabilities and accrued expenses		5,170,424
Liabilities assumed		24,838,085
Net Assets Acquired	$	10,898,979

Note 6 - Earnings Per Share - Schedule of Weighted Average Number of Shares (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Weighted-average common shares outstanding – basic (in shares)	27,339,180	25,391,084
Total (in shares)	27,339,180	27,011,482
Share-Based Payment Arrangement, Option [Member]
Stock options (in shares)		1,620,398

Note 2 - Summary of Significant Accounting Policies - Impact of Restatement (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash and cash equivalents	$ 33,206,712	$ 12,610,383
Restricted Cash, Current	6,338,306	0
Accounts receivable, net	8,010,708	20,569,497
Prepaid expenses	2,636,224	1,275,134
Total current assets	50,191,950	34,455,014
Operating lease right-of-use assets	2,615,204	3,053,022
Financing lease right-of-use assets	4,019,322	4,184,427
Equipment, net	24,314,455	14,845,470
Total assets	81,140,931	56,537,933
Accounts payable	4,458,525	7,382,361
Forward share purchase liability	6,338,306	0
Less: notes payable - current portion	1,796,724	538,731
Operating lease liabilities, current portion	1,142,413	924,265
Finance lease liabilities, current portion	161,050	194,717
Due to related party	2,367	16,778
Deferred grant income	100,000	100,000
Accrued expenses and other current liabilities	12,455,888	1,904,878
Total current liabilities	26,455,273	11,061,730
Operating lease liabilities, noncurrent	1,653,185	2,372,777
Finance lease liabilities, noncurrent	3,762,430	3,923,554
Warrant liabilities	10,720,130	0
Notes payable, noncurrent	0	172,037
Total liabilities	42,591,018	17,530,098
Commitments and contingencies (Note 17)
Preferred stock; $0.0001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding at December 31, 2021 and 2020	0	0
Common stock; $0.0001 par value; 490,000,000 shares authorized at December 31, 2021 and 2020; 43,487,279 and 25,973,406 shares issued and outstanding at December 31, 2021 and 2020, respectively	4,349	2,598
Additional paid-in capital	67,674,515	50,989,657
Accumulated deficit	(29,128,951)	(11,984,420)
Total	38,549,913	39,007,835	$ 7,694,433
Total liabilities and stockholders’ equity	81,140,931	56,537,933
Net (loss) income	(17,144,531)	20,117,773
Gain on debt extinguishment of Paycheck Protection Program SBA Loan	(665,596)	0
Depreciation, Depletion and Amortization	1,488,614	383,142
Amortization of right-of-use assets	164,983	165,036
Stock-based compensation expense	2,314,682	1,295,423
Gain on sale of equipment	(5,488)	(2,252)
Changes in fair value of warrant liabilities	4,151,068	(0)
Accounts receivable	12,558,790	(17,750,762)
Prepaid expenses	(1,258,348)	(1,151,130)
Right-of-use assets – operating lease	(63,626)	215,122
Accounts payable	(2,935,521)	5,211,593
Deferred income	0
Due to related party	(2,727)	10,528
Accrued expense and other current liabilities	3,384,573	1,410,322
Net cash provided by operating activities	1,986,873	10,004,795
Proceeds from the sale of equipment	0	9,000
Purchases of equipment	(10,943,657)	(12,731,702)
Net cash used in investing activities	(10,943,657)	(12,722,702)
Proceeds from Business Combination, net of transaction costs	34,340,225	0
Proceeds from issuance of notes payable	2,840,619	0
Payments of notes payable	(1,093,051)
Principal payments on finance leases	(203,124)	(182,347)
Proceeds from exercise of stock options	6,750	0
Net cash provided by financing activities	35,891,419	8,982,321
Net increase in cash, cash equivalents, and restricted cash	26,934,635	6,264,414
Beginning of year	12,610,383	6,345,969
End of year	39,545,018	12,610,383
Previously Reported [Member]
Cash and cash equivalents	33,206,712
Restricted Cash, Current	6,338,306
Accounts receivable, net	8,010,708
Prepaid expenses	864,513
Total current assets	48,420,239
Operating lease right-of-use assets	2,615,204
Financing lease right-of-use assets	4,019,322
Equipment, net	24,314,455
Total assets	79,369,220
Accounts payable	4,458,525
Forward share purchase liability	6,338,306
Less: notes payable - current portion	25,013
Operating lease liabilities, current portion	1,142,413
Finance lease liabilities, current portion	161,050
Due to related party	2,367
Deferred grant income	100,000
Accrued expenses and other current liabilities	12,455,888
Total current liabilities	24,683,562
Operating lease liabilities, noncurrent	1,653,185
Finance lease liabilities, noncurrent	3,762,430
Warrant liabilities	10,720,130
Notes payable, noncurrent	0
Total liabilities	40,819,307
Preferred stock; $0.0001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding at December 31, 2021 and 2020	0
Common stock; $0.0001 par value; 490,000,000 shares authorized at December 31, 2021 and 2020; 43,487,279 and 25,973,406 shares issued and outstanding at December 31, 2021 and 2020, respectively	4,349
Additional paid-in capital	67,674,515
Accumulated deficit	(29,128,951)
Total	38,549,913		(2,305,566)
Total liabilities and stockholders’ equity	79,369,220
Net (loss) income	(17,144,531)
Gain on debt extinguishment of Paycheck Protection Program SBA Loan	(665,596)
Depreciation, Depletion and Amortization	1,488,614
Amortization of right-of-use assets	164,983
Stock-based compensation expense	2,314,682
Gain on sale of equipment	(5,488)
Changes in fair value of warrant liabilities	4,151,068
Accounts receivable	12,558,790
Prepaid expenses	513,363
Right-of-use assets – operating lease	(63,626)
Accounts payable	(2,935,521)
Deferred income	0
Due to related party	(2,727)
Accrued expense and other current liabilities	3,384,573
Net cash provided by operating activities	3,758,584
Proceeds from the sale of equipment	0
Purchases of equipment	(10,943,657)
Net cash used in investing activities	(10,943,657)
Proceeds from Business Combination, net of transaction costs	34,340,225
Proceeds from issuance of notes payable	0
Payments of notes payable	(24,143)
Principal payments on finance leases	(203,124)
Proceeds from exercise of stock options	6,750
Net cash provided by financing activities	34,119,708
Net increase in cash, cash equivalents, and restricted cash	26,934,635
Beginning of year	12,610,383
End of year	39,545,018	12,610,383
Revision of Prior Period, Adjustment [Member]
Cash and cash equivalents	0
Restricted Cash, Current	0
Accounts receivable, net	0
Prepaid expenses	1,771,711
Total current assets	1,771,711
Operating lease right-of-use assets	0
Financing lease right-of-use assets	0
Equipment, net	0
Total assets	1,771,711
Accounts payable	0
Forward share purchase liability	0
Less: notes payable - current portion	1,771,711
Operating lease liabilities, current portion	0
Finance lease liabilities, current portion	0
Due to related party	0
Deferred grant income	0
Accrued expenses and other current liabilities	0
Total current liabilities	1,771,711
Operating lease liabilities, noncurrent	0
Finance lease liabilities, noncurrent	0
Warrant liabilities	0
Notes payable, noncurrent	0
Total liabilities	1,771,711
Preferred stock; $0.0001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding at December 31, 2021 and 2020	0
Common stock; $0.0001 par value; 490,000,000 shares authorized at December 31, 2021 and 2020; 43,487,279 and 25,973,406 shares issued and outstanding at December 31, 2021 and 2020, respectively	0
Additional paid-in capital	0
Accumulated deficit	0
Total	0		$ 9,999,999
Total liabilities and stockholders’ equity	1,771,711
Net (loss) income	0
Gain on debt extinguishment of Paycheck Protection Program SBA Loan	0
Depreciation, Depletion and Amortization	0
Amortization of right-of-use assets	0
Stock-based compensation expense	0
Gain on sale of equipment	0
Changes in fair value of warrant liabilities	0
Accounts receivable	0
Prepaid expenses	(1,771,711)
Right-of-use assets – operating lease	0
Accounts payable	0
Deferred income	0
Due to related party	0
Accrued expense and other current liabilities	0
Net cash provided by operating activities	(1,771,711)
Proceeds from the sale of equipment	0
Purchases of equipment	0
Net cash used in investing activities	0
Proceeds from Business Combination, net of transaction costs	0
Proceeds from issuance of notes payable	2,840,619
Payments of notes payable	(1,068,908)
Principal payments on finance leases	0
Proceeds from exercise of stock options	0
Net cash provided by financing activities	1,771,711
Net increase in cash, cash equivalents, and restricted cash	0
Beginning of year	0
End of year	$ 0	$ 0

Note 11 - Preferred Stock (Details Textual)	12 Months Ended
Note 11 - Preferred Stock (Details Textual)	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2022	Oct. 22, 2021 $ / shares shares	Oct. 21, 2021 shares	Dec. 31, 2020 $ / shares shares	Sep. 30, 2019 shares	Aug. 31, 2019 $ / shares shares
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	0			17,750,882	0
Preferred Stock, Convertible, Shares Issuable (in shares)			8,259,505
Preferred Stock, Shares Authorized (in shares)	10,000,000		10,000,000		10,000,000		50,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares	$ 0.0001		$ 0.0001		$ 0.0001
Amount of Preferred Stock Needed For Authorization to Modify Articles of Incorporation (in shares)						8,000,000
Preferred Stock, Convertible, Conversion Ratio		1
Convertible Preferred Stock, Conversion Term, Gross Proceeds From Common Stock \| $	$ 20,000,000
Series A Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)							6,615,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares							$ 1
Series A-1 Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)							2,525,800
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares							$ 1.88
Series A-2 Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)							4,039,963
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares							$ 3.00
Series A2A Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)							3,333,333
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares							$ 3.00
Preferred Stock, Redemption Price Per Share (in dollars per share) \| $ / shares					$ 5
Series B Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)							8,571,429
Preferred Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares							$ 3.50

Note 16 - Employee Benefit Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%	100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	3.00%	3.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount	$ 325,000	$ 188,000
Additional Employee Contributions [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	50.00%	50.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	2.00%	2.00%

Note 8 - Leases

12 Months Ended

Dec. 31, 2021

Lessee, Operating And Finance Leases [Text Block]

(8) Leases

The Company has an operating lease for lab space from Sanford Health (a related party), under a lease that started in June 2014 and ran through June 2019, at which time the lease was amended to run through August 2024. This lease can be terminated with one year advance written notice. The lease is for $66,993 per month. The operating lease does not include an option to extend beyond the life of the current term. The lease does not provide an implicit rate, and, therefore, the Company used an IBR of 4.54% as the discount rate when measuring the operating lease liability. The Company estimated the incremental borrowing rate based upon comparing interest rates available in the market for similar borrowings and the credit quality of the Company.

The Company entered into a lease for office, laboratory, and warehouse space in November 2020. This lease has a 3-year term, with options to extend for 3 additional periods of 3 years each. The options were not included in the right of use calculation as it is unclear as to whether or not the location will meet the Company’s requirements beyond the next three years. The lease cost is $36,125 per month. The Company used an IBR of 4.69% as the discount rate when measuring the operating lease liability. The Company estimated the incremental borrowing rate based upon comparing interest rates available in the market for similar borrowings and the credit quality of the Company.

The Company entered into a lease for barn space for the housing of goats in April 2020. This lease has a 2-year term, with automatic renewals for a one-year period after the initial term expires until either party terminates. The options were not included in the right of use calculation, as the goat project is mostly funded by government grants, and those grants do not currently extend beyond the initial lease term. The lease cost is $665 per month for the first year, then $678 per month for the second year. The Company used an IBR of 4.08% as the discount rate when measuring the operating lease liability. The Company estimated the incremental borrowing rate based upon comparing interest rates available in the market for similar borrowings and the credit quality of the Company.

The Company has the following finance leases:

	●	In December 2018, the Company entered into a finance lease with Dakota Ag Properties for a new animal facility which includes the surrounding land. The facility and the land have been accounted for as separate lease components. The lease is based upon payback of $4,000,000 in construction costs, with a 20-year term at an interest rate of 8%. The monthly payment for this lease is $33,458. The Company has the option to purchase the asset at any time during the term of the lease for the balance of the unamortized lease payments.
	●	In December 2018, the Company entered into an equipment lease for a 12,000-gallon propane tank that is located on the Company’s animal facility. The lease is for five years, with an annual payment of $8,199. The Company has the option to purchase the asset at any time during the term of the lease for the balance of the unamortized lease payments.
	●	In July 2018, the Company entered into a lease agreement with a bank, for a Ruby Cell Analyzer. The lease agreement is for a five-year term. The monthly payment for this lease is $807. The Company has the option to purchase the asset at the end of the lease for $1.
	●	In March 2019, the Company entered into two lease agreements for laboratory equipment. The leases are each for a 3-year term and a combined monthly payment of $5,956. Both leases have a $1 purchase option at the end of the lease term.

The lease agreements do not require material variable lease payments, residual value guarantees or restrictive covenants.

The amortizable lives of the operating lease assets are limited by their expected lease terms. The amortizable lives of the finance lease assets are limited by their expected lives, as the Company intends to exercise the purchase options at the end of the leases. The following is the estimated useful lives of the finance lease assets:

Animal Facility	40 years
Equipment	3 - 7 years
Land	Indefinite

The Company’s weighted-average remaining lease term and weighted-average discount rate for operating and finance leases as of December 31, 2021 are:

	*Operating*		*Finance*
Weighted-average remaining lease term	2.44 years		16.80 years
Weighted-average discount rate		4.58%		7.71%

The table below reconciles the undiscounted future minimum lease payments under non-cancelable leases with terms of more than one year to the total lease liabilities recognized on the consolidated balance sheet as of December 31, 2021:

	*Operating*			*Finance*
2022	$	1,240,333		$	444,928
2023		1,169,559			406,339
2024		535,943			401,496
2025		—			401,496
2026		—			401,496
Thereafter		—			4,784,494
Undiscounted future minimum lease payments		2,945,835			6,840,249
Less: Amount representing interest payments		(150,237	)		(2,916,769	)
Total lease liabilities		2,795,598			3,923,480
Less current portion		(1,142,413	)		(161,050	)
Noncurrent lease liabilities	$	1,653,185		$	3,762,430

Operating lease expense was approximately $1,083,000 and $710,000, respectively, for the years ended December 31, 2021 and 2020. Operating lease costs are included within research and development expenses on the consolidated statements of operations.

Finance lease costs for the years ended December 31, 2021 and 2020 included approximately $165,000 and $165,000, respectively, in right-of-use asset amortization and approximately $296,000 and $445,000, respectively, of interest expense. Finance lease costs are included within research and development expenses on the consolidated statements of operations.

Cash payments under operating and finance leases were approximately $1,147,000 and $491,000 , respectively, for the year ended December 31, 2021. Cash payments under operating and finance leases were approximately $564,000 and $491,000, respectively, for the year ended December 31, 2020.

Note 8 - Leases - Contractual Obligation Fiscal Year Maturity (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Operating lease liability, year one	$ 1,240,333
Finance lease liability, year one	444,928
Operating lease liability, year two	1,169,559
Finance lease liability, year two	406,339
Operating lease liability, year three	535,943
Finance lease liability, year three	401,496
Operating lease liability, year four	0
Finance lease liability, year four	401,496
Operating lease liability, year five	0
Finance lease liability, year five	401,496
Operating lease liability, thereafter	0
Finance lease liability, thereafter	4,784,494
Operating undiscounted future minimum lease payments	2,945,835
Finance undiscounted future minimum lease payments	6,840,249
Less: Amount representing operating interest payments	(150,237)
Less: Amount representing finance interest payments	(2,916,769)
Total operating lease liabilities	2,795,598
Total finance lease liabilities	3,923,480
Operating lease liabilities, current portion	(1,142,413)	$ (924,265)
Finance lease liabilities, current portion	(161,050)	(194,717)
Operating lease liabilities, noncurrent	1,653,185	2,372,777
Finance lease liabilities, noncurrent	$ 3,762,430	$ 3,923,554

Note 12 - Stock Option Plans (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Oct. 22, 2021	Dec. 31, 2019	Aug. 05, 2014
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number (in shares)	3,724,957	3,202,354
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)	12,500	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value	$ 28.9
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested	4.1
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value	$ 24.8
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.85%	0.13%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	6 years 3 months	6 years 3 months
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate	92.80%	106.10%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)	328,718	0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period (in shares)	0	0
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 6.6
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)	2 years 3 months 21 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Year)	5 years 9 months 10 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term (Year)	4 years 5 months 15 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)	461,701	400,632
2014 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)			7,444,800	16,000,000	8,000,000
Omnibus Equity Incentive Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	11,000,000

Note 17 - Commitments and Contingencies	12 Months Ended
Note 17 - Commitments and Contingencies	Dec. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	(17) Commitments and Contingencies The Company is not a party to any litigation, and, to its best knowledge, no action, suit or proceeding has been threatened against the Company which are expected to have a material adverse effect on its financial condition, results of operations or liquidity.

Note 16 - Employee Benefit Plan	12 Months Ended
Note 16 - Employee Benefit Plan	Dec. 31, 2021
Notes to Financial Statements
Defined Benefit Plan [Text Block]	(16) Employee Benefit Plan The Company sponsors a defined contribution retirement plan. All the Company’s employees are eligible to be enrolled in the employer-sponsored contributory retirement savings plan, which include features under Section 401(k) of the Internal Revenue Code of 1986, as amended, and provides for Company matching contributions. The Company’s contributions to the plan are determined by its Board of Directors, subject to certain minimum requirements specified in the plan. For the years ended December 31, 2021 and 2020 the Company made matching contributions of 100% on 3% of the employee contributions, with an additional 50% match on the next 2% of employee contributions, resulting in approximately $325,000 and $188,000, respectively, of matching contributions paid by the Company.

Note 2 - Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Cash and cash equivalents	$ 33,206,712	$ 12,610,383
Restricted cash	6,338,306	0
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$ 39,545,018	$ 12,610,383

Note 8 - Leases (Details Textual)	1 Months Ended				12 Months Ended
Note 8 - Leases (Details Textual)	Nov. 30, 2020 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($) bbl	Jul. 31, 2018 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Finance Lease Payments					$ 491,000	$ 491,000
Finance Lease, Right-of-Use Asset, Amortization					165,000	165,000
Finance Lease, Interest Expense					296,000	445,000
Operating Lease, Payments					1,147,000	564,000
Research and Development Expense [Member]
Operating Lease, Expense					$ 1,083,000	710,000
Dakota AG Properties [Member]
Sale Leaseback Transaction, Historical Cost			$ 4,000,000
Lessee, Finance Lease, Term of Contract (Year)			20 years
Lessee Finance Lease Interest Rate			8.00%
Finance Lease Payments			$ 33,458
Ruby Cell Analyzer [Member]
Lessee, Finance Lease, Term of Contract (Year)				5 years
Finance Lease Payments				$ 807
Payments for Purchase of Other Assets				$ 1
Laboratory Space [Member]
Lessee, Advanced Written Notice, Period (Year)					1 year
Operating Lease Payments Per Month					$ 66,993
Lessee, Operating Lease, Discount Rate					4.54%
Office Laboratory and Warehouse {Member]
Lessee, Operating Lease, Discount Rate	4.69%
Lessee, Operating Lease, Term of Contract (Year)	3 years
Operating Lease Number of Option to Extended Additional Period	3
Operating Lease Option to Extended Additional Period (Year)	3 years
Operating Lease Cost Per Month	$ 36,125
Barn Space [Member]
Lessee, Operating Lease, Discount Rate					4.08%
Lessee, Operating Lease, Term of Contract (Year)					2 years
Operating Lease Cost Per Month					$ 678	$ 665
Equipment [Member]
Lessee, Finance Lease, Term of Contract (Year)			5 years
Finance Lease Payments			$ 8,199
Finance Lease Propane Tank Volume (Barrel of Oil) \| bbl			12,000
Laboratory Equipment [Member]
Lessee, Finance Lease, Term of Contract (Year)		3 years
Finance Lease Payments		$ 5,956
Payments for Purchase of Other Assets		$ 1
Number of Lease Agreements		2

Note 10 - Notes Payable

12 Months Ended

Dec. 31, 2021

Debt Disclosure [Text Block]

(10) Notes Payable

As of December 31, 2021 and 2020, notes payable was as follows:

	*2021 (Restated)*		*2020*
Tractor loan	$	25,013	$	49,156
PPP loan		—		661,612
Insurance financing note payable		1,771,711		—
Total notes payable		1,796,724		710,768
Less: notes payable - current portion		1,796,724		538,731
Notes payable, noncurrent	$	—	$	172,037

On November 15, 2017, the Company entered into a loan agreement with a bank, for the financing of an ultrasound machine for $18,997. The agreement was for a four-year term, with monthly payments of $440. The note payable was paid off in full in September 2020.

In December 2017, the Company entered into a loan agreement for the purchase of a tractor for $116,661 at a 3.6% interest rate. The loan included annual payments of $25,913 for the next five years starting in December 2018. The tractor loan balance as of December 31, 2021 and 2020 was $25,013 and $49,156, respectively. The total amount of the remaining loan balance is due in full in 2022.

On March 27, 2020, President Trump signed into law the “Coronavirus Aid, Relief and Economic Security Act (“CARES Act”). In April 2020, the Company entered into a loan agreement (the “PPP Loan”) with First Premier Bank under the Paycheck Protection Program (the “PPP”), which is part of the CARES Act administered by the United States Small Business Administration (“SBA”). As part of the application for these funds, the Company, in good faith, certified that the current economic uncertainty made the loan request necessary to support the ongoing operations of the Company. The certification further requires the Company to take into account its current business activity and its ability to access other sources of liquidity sufficient to support ongoing operations in a manner that is not significantly detrimental to the business. Under the PPP, the Company received proceeds of approximately $661,612. In accordance with the requirements of the PPP, the Company utilized the proceeds from the PPP Loan primarily for payroll costs. The PPP Loan has a 1.00% interest rate per annum, matures in April 2022 and is subject to the terms and conditions applicable to loans administered by the SBA under the PPP. Under the terms of PPP, all or certain amounts of the PPP Loan may be forgiven if they are used for qualifying expenses, as described in the CARES Act. The Company recorded the entire amount of the PPP Loan as debt. In February 2021, the Company submitted a forgiveness application related to its PPP Loan. In March 2021, the SBA approved the forgiveness of the PPP Loan, plus accrued interest. We recorded a gain on extinguishment of PPP Loan of $665,596 for the forgiveness of the PPP Loan and accrued interest within gain on debt extinguishment of Paycheck Protection Program SBA Loan on the consolidated statement of operations for the year ended December 31, 2021.

Note payable, related party

On February 24, 2016, the Company entered into a loan agreement with Christiansen Land and Cattle, Ltd. (“CLC”), a related party, for a $3.0 million revolving line of credit secured by a blanket security interest in the assets of the Company.

The Company borrowed $2.5 million from the line of credit in 2016, and $350,000 in 2017. The line of credit bears a fixed rate per annum of 6% compounded annually. The initial agreement was based upon repayment following a significant capital event – closing of equity or debt financing with total proceeds to the Company of $15 million or more or one year from the agreement date, whichever occurred first. The agreement was amended in August 2018 to extend the repayment timeframe to August 31, 2019. The first payment to repay this loan was made on August 31, 2018 ( $1.0 million payment). Additional voluntary payments were being made at the rate of $30,000 per month. In August 2019, the agreement was amended to extend the maturity date to the earlier of August 31, 2020 or the occurrence of a significant capital event, as defined above. In July 2020, the note payable was paid in full.

Insurance Funding

The Company obtained financing for certain Director & Officer liability insurance policy premiums. The agreement assigns First Insurance Funding (Lender) a first priority lien on and security interest in the financed policies and any additional premium required in the financed policies including (a) all returned or unearned premiums, (b) all additional cash contributions or collateral amounts assessed by the insurance companies in relation to the financed policies and financed by Lender, (c) any credits generated by the financed policies, (d) dividend payments, and (e) loss payments which reduce unearned premiums. If any circumstances exist in which premiums related to any Financed Policy could become fully earned in the event of loss, Lender shall be named a loss-payee with respect to such policy.

The total premiums, taxes and fees financed is approximately $2,841,000 with an annual interest rate of 2.85%. In consideration of the premium payment by Lender to the insurance companies or the Agent or Broker, the Company unconditionally promise to pay Lender the amount Financed plus interest and other charges permitted under the Agreement. At December 31, 2021 the Company recognized approximately $1,772,000 as insurance financing note payable in its consolidated balance sheet. The Company will pay the insurance financing through installment payments with the last payment being on September 22, 2022.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Note 9 - Accrued Expenses and Other Current Liabilities

12 Months Ended

Dec. 31, 2021

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

(9) Accrued Expenses and Other Current Liabilities

As of December 31, 2021 and 2020, accrued expenses and other current liabilities consisted of the following:

	*2021*		*2020*
Accrued vacation	$	552,629	$	438,936
Accrued payroll		674,858		314,451
Accrued construction-in-progress		548,988		637,776
Accrued supplies		709,027		301,989
Accrued consulting		179,082		120,744
Accrued clinical trial expense		423,634		—
Accrued outside laboratory services		128,752		—
Accrued bonus & severance		1,804,288		—
Accrued contract manufacturing		1,000,824		—
Accrued legal		833,646		—
Accrued financing fees payable		5,100,000		—
Accrued franchise tax payable		216,251		—
Other accrued expenses		283,909		90,982
		12,455,888		1,904,878

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
Consolidated Statements of Cash Flows - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net (loss) income	$ (17,144,531)	$ 20,117,773
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Gain on debt extinguishment of Paycheck Protection Program SBA Loan	(665,596)	0
Depreciation and amortization	1,488,614	383,142
Amortization of right-of-use assets	164,983	165,036
Stock-based compensation expense	2,314,682	1,295,423
Gain on sale of equipment	(5,488)	(2,252)
Changes in fair value of warrant liabilities	4,151,068	(0)
Changes in operating assets and liabilities
Accounts receivable	12,558,790	(17,750,762)
Prepaid expenses	(1,258,348)	(1,151,130)
Right-of-use assets – operating lease	(63,626)	215,122
Accounts payable	(2,935,521)	5,211,593
Deferred income	0	100,000
Due to related party	(2,727)	10,528
Accrued expense and other current liabilities	3,384,573	1,410,322
Net cash provided by operating activities	1,986,873	10,004,795
Cash flows from investing activities:
Proceeds from the sale of equipment	0	9,000
Purchases of equipment	(10,943,657)	(12,731,702)
Net cash used in investing activities	(10,943,657)	(12,722,702)
Cash flows from financing activities:
Proceeds from Business Combination, net of transaction costs	34,340,225	0
Proceeds from the sale of stock, net of issuance costs	0	9,900,206
Payments on related party notes payable	0	(1,364,644)
Proceeds from issuance of notes payable	(2,840,619)	0
Payments of notes payable	(1,093,051)	(32,506)
Principal payments on finance leases	(203,124)	(182,347)
Proceeds from exercise of stock options	6,750	0
Net cash provided by financing activities	35,891,419	8,982,321
Net increase in cash, cash equivalents, and restricted cash	26,934,635	6,264,414
Cash, cash equivalents, and restricted cash
Beginning of year	12,610,383	6,345,969
End of year	39,545,018	12,610,383
Supplemental information on non-cash investing and finance activities:
Right-of-use assets obtained in exchange for operating lease liabilities	505,187	1,773,135
Warrant liabilities assumed related to the Business Combination	6,569,062	0
Liabilities assumed related to the Forward Share Purchase Agreement	6,338,306	0
Financing fee liabilities assumed related to the Business Combination included in accrued expense and other current liabilities	3,100,000	0
Unpaid financing fees included in accrued expense and other current liabilities	2,000,000	0
Cash and cash equivalents	33,206,712	12,610,383
Plus: restricted cash - Forward Share Purchase Agreement	6,338,306	0
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	39,545,018	12,610,383
Paycheck Protection Program Loan [Member]
Cash flows from financing activities:
Proceeds from Paycheck Protection Program SBA Loan	$ 0	$ 661,612

Note 6 - Earnings Per Share (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	*Year Ended December 31, 2021*
Calculation of basic and diluted EPS attributable to the Company’s shareholders
Net loss attributable to the Company’s shareholders	$	(17,144,531	)
Weighted-average common shares outstanding – basic and diluted		27,339,180
Net loss per common share, basic and diluted	$	(0.63	)

	*Year Ended December 31, 2020*
Calculation of basic EPS attributable to the Company’s shareholders
Net income attributable to the Company’s shareholders	$	20,117,773
Weighted-average common shares outstanding – basic		25,391,084
Net earnings per share, basic	$	0.79
Calculation of diluted EPS attributable to the Company’s shareholders
Net income attributable to the Company’s shareholders	$	20,117,773
Weighted-average common shares outstanding – diluted		27,011,482
Net earnings per share, diluted	$	0.74

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	*Year Ended December 31, 2021*
Stock options		3,724,957
Common stock warrants		5,958,600
Earnout shares (1)		10,491,937
Contingently issuable earnout shares from unexercised Rollover Options		1,508,063
Total		21,683,557

Schedule of Weighted Average Number of Shares [Table Text Block]

	*Year Ended December 31, 2020*
Weighted-average common shares outstanding – basic		25,391,084
Stock options		1,620,398
Total		27,011,482

Note 9 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accrued vacation	$ 552,629	$ 438,936
Accrued payroll	674,858	314,451
Accrued construction-in-progress	548,988	637,776
Accrued supplies	709,027	301,989
Accrued consulting	179,082	120,744
Accrued clinical trial expense	423,634	0
Accrued outside laboratory services	128,752	0
Accrued bonus & severance	1,804,288	0
Accrued contract manufacturing	1,000,824	0
Accrued legal	833,646	0
Accrued financing fees payable	5,100,000	0
Accrued franchise tax payable	216,251	0
Other accrued expenses	283,909	90,982
Accounts Payable and Other Accrued Liabilities, Current	$ 12,455,888	$ 1,904,878

Note 9 - Accrued Expenses and Other Current Liabilities (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Accrued Liabilities [Table Text Block]

	*2021*		*2020*
Accrued vacation	$	552,629	$	438,936
Accrued payroll		674,858		314,451
Accrued construction-in-progress		548,988		637,776
Accrued supplies		709,027		301,989
Accrued consulting		179,082		120,744
Accrued clinical trial expense		423,634		—
Accrued outside laboratory services		128,752		—
Accrued bonus & severance		1,804,288		—
Accrued contract manufacturing		1,000,824		—
Accrued legal		833,646		—
Accrued financing fees payable		5,100,000		—
Accrued franchise tax payable		216,251		—
Other accrued expenses		283,909		90,982
		12,455,888		1,904,878

Note 12 - Stock Option Plans - Schedule of Share Based Compensation Allocation Recognized Period Costs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Allocated share-based compensation expense	$ 2,314,682	$ 1,295,423
Research and Development Expense [Member]
Allocated share-based compensation expense	964,926	635,824
General and Administrative Expense [Member]
Allocated share-based compensation expense	$ 1,349,756	$ 659,599

Note 13 - Fair Value Measurements (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Recurring [Member]
Liabilities, Fair Value Disclosure, Total	$ 0	$ 0
Assets, Fair Value Disclosure, Total	$ 0	$ 0
Public Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 11.50
Warrants and Rights Outstanding, Term (Year)	5 years
Warrants or Rights, Redemption Price (in dollars per share)	$ 0.01
Warrants and Rights Outstanding, Minimum Share Price to Call (in dollars per share)	$ 18.00
Class of Warrant or Right, Outstanding (in shares)	5,750,000
Private Placement Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)	208,600
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)	$ 4,000
Private Placement Warrants [Member] \| Changes in Fair Value of Warrant Liabilities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings	$ 6,300

Note 12 - Stock Option Plans (Tables)

12 Months Ended

Dec. 31, 2021

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

	*Options*		*Weighted Average Fair Value*		*Weighted Average Exercise Price*
Balance, December 31, 2019		3,139,855	$	0.82	$	0.88
Granted		962,088	$	3.44	$	2.69
Balance, December 31, 2020		4,101,943	$	1.43	$	1.30
Granted		1,346,947	$	5.36	$	5.81
Forfeited		328,718	$	2.17	$	2.06
Exercised		12,500	$	0.39	$	0.54
Balance, December 31, 2021		5,107,672	$	2.30	$	2.44
Unvested at December 31, 2021		1,382,715	$	5.41	$	5.92
Vested and exercisable at December 31, 2021		3,724,957	$	1.14	$	1.16

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	*2021*		*2020*
Research and development	$	964,926	$	635,824
General and administrative		1,349,756		659,599
Total	$	2,314,682	$	1,295,423

Note 3 - New Accounting Standards

12 Months Ended

Dec. 31, 2021

Accounting Standards Update and Change in Accounting Principle [Text Block]

(3) New accounting standards

Recently-adopted standards

In December 2019, the FASB issued Accounting Standards Update (“ASU”) 2019- 12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in ASC Topic 740, Income Taxes (“ASC 740”) and by clarifying and amending existing ASC 740 guidance. The guidance was effective for fiscal years, and interim periods within those years, beginning after December 15, 2020. Early adoption was permitted. The Company adopted the guidance as of January 1, 2021. The adoption did not have a material impact on the Company’s consolidated financial statements.

In August 2020, the FASB issued ASU 2020- 06, Debt— Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’ s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’ s Own Equity, which simplifies the accounting for convertible instruments by removing major separation models required under current U.S. GAAP. The guidance removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for such exception and simplifies the diluted earnings per share calculation in certain areas. The guidance is effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted in annual reporting periods ending after December 15, 2020. The Company early adopted the guidance as of January 1, 2021. The adoption did not have a material impact on the Company’s consolidated financial statements.

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI https://asc.fasb.org/topic&trid=2122394

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 105
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-URI https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-URI https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section S99
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(2)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 10
-Section 65
-Paragraph 5
-Subparagraph (f)(3)
-URI https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (c)(3)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 926
-SubTopic 20
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-URI https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 848
-SubTopic 10
-Section 65
-Paragraph 2
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-URI https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277

Note 6 - Earnings Per Share - Schedule of Earnings Per Share Basic and Diluted (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Net (loss) income	$ (17,144,531)	$ 20,117,773
Weighted-average common shares outstanding – basic (in shares)	27,339,180	25,391,084
Basic (loss) earnings per common share (in dollars per share)	$ (0.63)	$ 0.79
Weighted-average common shares outstanding – diluted (in shares)	27,339,180	27,011,482
Diluted (loss) earnings per common share (in dollars per share)	$ (0.63)	$ 0.74

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Note 7 - Equipment - Construction in Progress (Details) - Construction in Progress [Member] - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Construction in progress	$ 4,608,778	$ 6,729,673
The 200L Commercial Facility [Member]
Construction in progress	0	4,148,113
The 200L Commercial Facility Equipment [Member]
Construction in progress	0	486,381
New Animal Barn 6 [Member]
Construction in progress	0	1,551,167
New Office Space [Member]
Construction in progress	11,183	477,907
Laboratory Space [Member]
Construction in progress	2,506,482	0
Laboratory Equipment [Member]
Construction in progress	246,801	0
IT Equipment [Member]
Construction in progress	212,209	0
Software [Member]
Construction in progress	137,811	0
Bioreactors [Member]
Construction in progress	1,280,728	0
Other Segments [Member]
Construction in progress	$ 213,564	$ 66,105

Note 4 - Reverse Recapitalization and Business Combination - Schedule of Recognized Assets Acquired and Liabilities Assumed (Details)	Oct. 22, 2021 USD ($)
BCYP trust and cash, net of redemptions	$ 22,535,723
Restricted cash - Forward Share Purchase Agreement	13,098,599
Other assets	102,742
Assets acquired	35,737,064
Forward share purchase liability	13,098,599
Fair value of redeemable warrants	6,569,062
Other liabilities and accrued expenses	5,170,424
Liabilities assumed	24,838,085
Net Assets Acquired	$ 10,898,979

Consolidated Statements of Changes In Redeemable Preferred Stock and Stockholders' Equity (Deficit) - USD ($)	Previously Reported [Member] Preferred Stock [Member] Series A-2A Redeemable Preferred Stock [Member]	Previously Reported [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Previously Reported [Member] Preferred Stock [Member] Series A-1 Preferred Stock [Member]	Previously Reported [Member] Preferred Stock [Member] Series A-2 Preferred Stock [Member]	Previously Reported [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Previously Reported [Member] Common Stock [Member]	Previously Reported [Member] Additional Paid-in Capital [Member]	Previously Reported [Member] Retained Earnings [Member]	Previously Reported [Member]	Revision of Prior Period, Adjustment [Member] Preferred Stock [Member] Series A-2A Redeemable Preferred Stock [Member]	Revision of Prior Period, Adjustment [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Revision of Prior Period, Adjustment [Member] Preferred Stock [Member] Series A-1 Preferred Stock [Member]	Revision of Prior Period, Adjustment [Member] Preferred Stock [Member] Series A-2 Preferred Stock [Member]	Revision of Prior Period, Adjustment [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Revision of Prior Period, Adjustment [Member] Common Stock [Member]	Revision of Prior Period, Adjustment [Member] Additional Paid-in Capital [Member]	Revision of Prior Period, Adjustment [Member] Retained Earnings [Member]	Revision of Prior Period, Adjustment [Member]	Big Cypress Acquisition Corp [Member] Preferred Stock [Member] Series A-2A Redeemable Preferred Stock [Member]	Big Cypress Acquisition Corp [Member] Preferred Stock [Member] Series A Preferred Stock [Member]	Big Cypress Acquisition Corp [Member] Preferred Stock [Member] Series A-1 Preferred Stock [Member]	Big Cypress Acquisition Corp [Member] Preferred Stock [Member] Series A-2 Preferred Stock [Member]	Big Cypress Acquisition Corp [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Big Cypress Acquisition Corp [Member] Common Stock [Member]	Big Cypress Acquisition Corp [Member] Additional Paid-in Capital [Member]	Big Cypress Acquisition Corp [Member] Retained Earnings [Member]	Big Cypress Acquisition Corp [Member]	Preferred Stock [Member] Series A-2A Redeemable Preferred Stock [Member]	Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Series A-1 Preferred Stock [Member]	Preferred Stock [Member] Series A-2 Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019	3,333,333	6,615,000	2,525,800	4,039,963	1,236,786	35,216,000				(3,333,333)	(6,615,000)	(2,525,800)	(4,039,963)	(1,236,786)	(10,570,449)													0	0	0	0	0	24,645,551
Balance at Dec. 31, 2019	$ 9,999,999	$ 662	$ 253	$ 404	$ 124	$ 3,522	$ 29,791,662	$ (32,102,193)	$ (2,305,566)	$ (9,999,999)	$ (662)	$ (253)	$ (404)	$ (124)	$ (1,057)	$ 10,002,499	$ 0	$ 9,999,999										$ 0	$ 0	$ 0	$ 0	$ 0	$ 2,465	$ 39,794,161	$ (32,102,193)	$ 7,694,433
Issuance of stock in private offerings, net of issuance cost of $87,949 (in shares)																												0	0	0
Issuance of stock in private offerings, net of issuance cost of $87,949																												$ 0	$ 0	$ 0
Stock-based compensation																												0		0	0	0	0	1,295,423	0	1,295,423
Net (loss) income																												$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	0	20,117,773	20,117,773
Balance (in shares) at Dec. 31, 2020																												0	0	0	0	0	25,973,406
Balance at Dec. 31, 2020																												$ 0	$ 0	$ 0	$ 0	$ 0	$ 2,598	50,989,657	(11,984,420)	39,007,835
Stock-based compensation																												0		0	0	0	0	2,314,682	0	2,314,682
Net (loss) income									(17,144,531)									0										$ 0		$ 0	$ 0	$ 0	$ 0	0	(17,144,531)	(17,144,531)
Effect of Business Combination and recapitalization, net of redemptions and issuance costs of $3,294,096 (in shares)																			0	0	0	0	0	7,009,436
Effect of Business Combination and recapitalization, net of redemptions and issuance costs of $3,294,096																			$ 0	$ 0	$ 0	$ 0	$ 0	$ 701	$ 7,603,133	$ 0	$ 7,603,834
Issuance of restricted stock, subject to forfeiture (in shares)																												0	0	0	0	0	10,491,937
Issuance of restricted stock, subject to forfeiture																												$ 0	$ 0	$ 0	$ 0	$ 0	$ 1,049	0	0	1,049
Forward Share Purchase Agreement, partial settlement																												$ 0		$ 0	$ 0	$ 0	$ 0	6,760,294	0	6,760,294
Issuance of common stock for exercise of stock options (in shares)																												0	0	0	0	0	12,500
Issuance of common stock for exercise of stock options																												$ 0	$ 0	$ 0	$ 0	$ 0	$ 1	6,749	0	6,750
Balance (in shares) at Dec. 31, 2021																												0	0	0	0	0	43,487,279
Balance at Dec. 31, 2021									$ 38,549,913									$ 0									$ 7,604,883	$ 0	$ 0	$ 0	$ 0	$ 0	$ 4,349	$ 67,674,515	$ (29,128,951)	$ 38,549,913

Note 14 - Income Taxes

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Text Block]

(14) Income Taxes

Net deferred tax assets as of December 31, 2021 and 2020 consisted of the following:

	*2021*			*2020*
Deferred tax assets:
Net operating loss carryforwards	$	5,078,429		$	2,659,082
Stock-based compensation		1,156,235			600,592
Vacation accrual		99,300			84,553
Lease liabilities		623,286			727,587
Other accrued expenses		1,119,721			—
Start-up costs		297,136			—
Total deferred tax assets	$	8,374,107		$	4,071,814
Less valuation allowance		(5,300,689	)		(2,320,958	)
Total deferred tax assets after valuation allowance		3,073,418			1,750,856
Deferred tax liabilities:
Operating lease right-of-use asset		551,547			641,135
Depreciation and amortization		2,521,871			1,109,721
Total deferred tax liabilities		3,073,418			1,750,856
Net deferred tax asset (liability)	$	—		$	—

The reconciliation between the Company’s effective tax rate and the statutory tax rate of 21% includes the following significant items: changes in the valuation allowance and permanent items including meals and entertainment. The rate reconciliation was as follows:

	*2021*					*2020*
Rate reconciliation:
Net (loss) income before tax	$	(17,144,531	)			$	20,117,773
Federal income tax at statutory rate		(3,600,352	)	21.00	%		4,224,732		21.00	%
State income tax		(9,849	)	0.06	%		—		—	%
Permanent items		1,029,874		(6.01	)%		918		(0.01	)%
Valuation allowance		2,679,238		(15.63	)%		(4,225,651	)	(20.99	)%
Other		(98,911	)	0.58	%		1		—	%
	$	—		—	%	$	—		—	%

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of the deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based upon the level of historical losses and the uncertainty of future taxable income over the periods which the Company will realize the benefits of its net deferred tax assets, management believes it is more likely than not that the Company will not fully realize the benefits on the balance of its net deferred tax asset and, accordingly, the Company has established a valuation allowance on its net deferred tax assets. The valuation allowance increased by approximately $2,980,000 and decreased by approximately $4,226,000, respectively, for the years ended December 31, 2021 and 2020.

As of December 31, 2021, the Company had approximately $25,175,483 of federal net operating losses, which were generated after December 31, 2017 and can be carried forward indefinitely under the Tax Cuts and Jobs Act and may generally be used to offset up to 80% of future taxable income.

The Company has historically experienced ownership change(s) pursuant to Section 382 of the Internal Revenue Code ("the Code") of 1986, as amended, as well as similar state provisions. Utilization of the Company’s net operating loss carryforwards are subject to annual limitation(s) due to historical ownership change(s) that have occurred and may be further restricted in the event future ownership changes occur. These ownership changes may limit the amount of the net operating loss carryover that can be utilized annually to offset future taxable income. In general, an “ownership change”, as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders.

U.S. GAAP provides that the tax effects from uncertain tax positions can be recognized in the consolidated financial statements only if the position is more likely than not of being sustained on audit, based on the technical merits of the position. As of December 31, 2021 and 2020, there were no uncertain tax provisions. There was no interest or penalties related to income taxes for the years ended December 31, 2021 and 2020, and there was no accrued interest or penalties associated with uncertain tax positions as of December 31, 2021 and 2020.

The Company files tax returns as prescribed by the laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company’s tax years are still open under the statute from 2018 to present. However, to the extent allowed by law, the taxing authorities may have the right to examine the period from 2015 through 2021 where net operating losses were generated and carried forward and make adjustments to the amount of the net operating loss carryforward amount. The Company is not currently under examination by federal or state jurisdictions.

As discussed in Note 10, Notes Payable, on March 27, 2020, the CARES Act was enacted in response to the COVID- 19 pandemic. It was determined the CARES Act did not materially impact the Company’s tax provision as of December 31, 2021.

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Note 6 - Earnings Per Share

12 Months Ended

Dec. 31, 2021

Earnings Per Share [Text Block]

(6) Earnings per share

On the Closing Date, the Company completed the Business Combination with BCYP, whereby the Company received 36,465,343 shares in exchange for all of its share capital. The effect of the Business Combination was recast to reflect the Exchange Ratio to January 1, 2020, and will be utilized for the calculation of earnings per share in all prior periods. The per share amounts have been updated to show the effect of the exchange on earnings per share as if the exchange occurred at the beginning of both years for the annual financial statements of the Company. The impact of the stock exchange is also shown on the Company’s consolidated statements of changes in redeemable preferred stock and stockholders’ equity (deficit).

Since the Company reported a net loss for the year ended December 31, 2021, it was required by ASC 260 to use basic weighted-average shares outstanding when calculating diluted net loss per share for the year ended December 31, 2021, as the potential dilutive securities are anti-dilutive.

	*Year Ended December 31, 2021*
Calculation of basic and diluted EPS attributable to the Company’s shareholders
Net loss attributable to the Company’s shareholders	$	(17,144,531	)
Weighted-average common shares outstanding – basic and diluted		27,339,180
Net loss per common share, basic and diluted	$	(0.63	)

The shares in the table below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:

	*Year Ended December 31, 2021*
Stock options		3,724,957
Common stock warrants		5,958,600
Earnout shares (1)		10,491,937
Contingently issuable earnout shares from unexercised Rollover Options		1,508,063
Total		21,683,557

(1)	As the Earnout shares are subject to certain vesting requirements not satisfied as of the year ended December 31, 2021, the Earnout Shares held in escrow are excluded from calculating both basic and diluted earnings per share.

The following is a reconciliation of the numerator and denominator used to calculate basic earnings per share and diluted earnings per share for the year ended December 31, 2020:

	*Year Ended December 31, 2020*
Calculation of basic EPS attributable to the Company’s shareholders
Net income attributable to the Company’s shareholders	$	20,117,773
Weighted-average common shares outstanding – basic		25,391,084
Net earnings per share, basic	$	0.79
Calculation of diluted EPS attributable to the Company’s shareholders
Net income attributable to the Company’s shareholders	$	20,117,773
Weighted-average common shares outstanding – diluted		27,011,482
Net earnings per share, diluted	$	0.74

The following table reconciles the weighted-average common shares outstanding used in the calculation of basic earnings per share (“EPS”) to the weighted-average common shares outstanding used in the calculation of diluted EPS for the year ended December 31, 2020:

	*Year Ended December 31, 2020*
Weighted-average common shares outstanding – basic		25,391,084
Stock options		1,620,398
Total		27,011,482

Note 18 - Joint Development Agreement	12 Months Ended
Note 18 - Joint Development Agreement	Dec. 31, 2021
Notes to Financial Statements
Joint Development Agreement [Text Block]	(18) Joint Development Agreement In June 2019, the Company entered into a joint development agreement with the University of South Dakota Research Park, Inc. (“USDRP”) for the construction of a multi-tenant office building and a manufacturing building. Pursuant to the agreement, the Company also entered into a lease agreement for 41,195 square feet of leasable area located in the building. The lease will commence upon completion of the building for an initial term of 12 years at a monthly payment of approximately $118,000. Aurochs, LLC, a wholly owned subsidiary, was founded to manage the construction funds for this project. All pre-construction costs up to a budgeted $2.7 million were paid directly by the Company and reimbursed by USDRP. As of December 31, 2021 and 2020, USDRP has spent approximately $2.12 million in design costs for this facility, with approximately $580,000 of the $2.7 million budget remaining. There were no receivables or payables for this project as of December 31, 2021 and 2020. USDRP and the Company intend to secure outside funding for all expenses incurred after the pre-construction phase. If funding cannot be secured to finance the construction of this facility, the Company will not be required to refund any of the design costs incurred to date. Due to the work around SARS- 2 and the JPEO contract (please refer to Note 5, Revenue, for additional information), this project is on hold as the Company focuses on development of our current internal manufacturing capabilities and completion of the JPEO contract work which will continue through the end of 2022.

Note 19 -Subsequent Events (Details Textual)		1 Months Ended	12 Months Ended
Note 19 -Subsequent Events (Details Textual)	Mar. 28, 2022 USD ($) a	Jan. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Restricted Cash, Current			$ 6,338,306	$ 0
Operating Lease, Payments			1,147,000	$ 564,000
Subsequent Event [Member] \| Lease Agreement [Member] \| Sanford Health [Member]
Area of Real Estate Property (Square Foot) \| a	4,035
Operating Lease Payments Per Square Foot	$ 25.27
Operating Lease, Payments	841,061
Operating Lease Payments Per Month	$ 70,088
Forward Share Purchase Agreement [Member]
Restricted Cash, Current			$ 6,300,000
Forward Share Purchase Agreement [Member] \| Subsequent Event [Member]
Stock Repurchased During Period, Shares (in shares) \| shares		546,658
Payments for Repurchase of Common Stock		$ 5,500,000
Restricted Cash, Current		$ 800,000

Note 5 - Revenue (Details Textual) - USD ($)	12 Months Ended
Note 5 - Revenue (Details Textual) - USD ($)	Dec. 31, 2021	Dec. 31, 2020	Sep. 01, 2019	Aug. 01, 2019	Apr. 01, 2019	Aug. 01, 2017
Governmental Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 60,900,000	$ 52,800,000
National Institute of Health [Member]
Revenue from Contract with Customer, Including Assessed Tax	518,000	228,000
Deferred Revenue, Total	203,000		$ 1,400,000
Federal Award [Member]
Revenue from Contract with Customer, Including Assessed Tax	51,000	99,000
Deferred Revenue, Total	823,000				$ 1,500,000
Geneva Foundation [Member]
Revenue from Contract with Customer, Including Assessed Tax	94,000	351,000
Deferred Revenue, Total	1,500,000					$ 2,700,000
Advanced Technology International [Member]
Revenue from Contract with Customer, Including Assessed Tax	60,200,000	52,100,000
Deferred Revenue, Total	$ 89,200,000	204,000,000		$ 25,000,000
Revenue, Remaining Performance Obligation, Percentage	9.00%
Revenue, Remaining Performance Obligation, Amount		12,000,000
Non Government [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 0	2,400,000
CSL Behring [Member]
Revenue from Contract with Customer, Including Assessed Tax		2,400,000
CSL Behring [Member] \| COVID-19 Therapeutic [Member]
Revenue from Contract with Customer, Including Assessed Tax		2,000,000
CSL Behring [Member] \| Product and Service, Other [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 400,000

Consolidated Statements of Changes In Redeemable Preferred Stock and Stockholders' Equity (Deficit) (Parentheticals) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Big Cypress Acquisition Corp [Member]
Issuance costs	$ 3,294,096
Issuance costs		$ 87,949

Note 6 - Earnings Per Share (Details Textual)	Oct. 22, 2021 shares
Big Cypress Acquisition Corp [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)	36,465,343

Note 1 - Nature of Business

12 Months Ended

Dec. 31, 2021

Nature of Operations [Text Block]

(1) Nature of Business

On October 22, 2021 (the "Closing Date"), we consummated the business combination contemplated by the agreement and plan of merger, dated as of June 21, 2021, as amended on August 12, 2021, made by and among Big Cypress Acquisition Corp., a Delaware corporation (“BCYP”), Big Cypress Merger Sub Inc., a Delaware corporation (“Merger Sub”), SAB Biotherapeutics, Inc., a Delaware corporation (“SAB” or the “Company”), and Shareholder Representative Services LLC, a Colorado limited liability company, solely in its capacity as the representative, agent and attorney-in-fact of the SAB Stockholders. Upon closing of the Business combination, Big Cypress Merger Sub merged with SAB Biotherapeutics, with SAB Biotherapeutics as the surviving company of the merger. Upon closing of the business combination, Big Cypress Acquisition Corp. changed its name to “SAB Biotherapeutics, Inc.”.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. SAB’s novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine™) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. However, SAB's platform is the first to produce fully human antibodies in large animals.

The COVID- 19 pandemic continues to evolve, and the extent to which it may impact the Company’s business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the U.S. and other countries, business closures or business disruptions, and the effectiveness of actions taken in the U.S. and other countries to contain and treat the disease. The Company is following, and will continue to follow, recommendations from the U.S. Centers for Disease Control and Prevention, as well as federal, state, and local governments. To date, the Company has not experienced material business disruptions, but it cannot be certain of the future impact of the COVID- 19 pandemic on its business and consolidated financial statements.

Note 7 - Equipment

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment Disclosure [Text Block]

(7) Equipment

As of December 31, 2021 and 2020, the Company’s equipment was as follows:

	*2021*		*2020*
Laboratory equipment	$	7,431,988	$	5,205,346
Animal facility		8,357,667		3,371,125
Animal facility equipment		1,253,879		1,003,629
Construction-in-progress		4,608,778		6,729,673
Leasehold improvements		5,700,364		185,971
Vehicles		135,593		96,693
Office furniture and equipment		46,202		20,219
Less: accumulated depreciation and amortization		3,220,016		1,767,186
Property, plant and equipment net	$	24,314,455	$	14,845,470

Depreciation and amortization expense for the years ended December 31, 2021 and 2020 was $1,488,614 and $383,142, respectively.

All tangible personal property with a useful life of at least three years and a unit acquisition cost of $5,000 or more will be capitalized and depreciated over its useful life using the straight-line method of depreciation. The Company will expense the full acquisition cost of tangible personal property below these thresholds in the year of purchase. The basis of accounting for depreciable fixed assets is acquisition cost and any additional expenditures required to make the asset ready for use. The carrying amount at the balance sheet date of long-lived assets under construction-in-progress includes assets purchased, constructed, or being developed internally that are not yet in service. Depreciation commences when the assets are placed in service.

The Company has several ongoing construction projects related to the expansion of its operating capacity. As of December 31, 2021 and 2020, the Company’s construction-in-progress was as follows:

	*2021*		*2020*
200L commercial facility	$	—	$	4,148,113
200L commercial facility equipment		—		486,381
New animal barn (#6)		—		1,551,167
New office space (at Headquarters)		11,183		477,907
Laboratory space at Headquarters		2,506,482		—
Lab equipment at Headquarters		246,801		—
IT equipment for new office space		212,209		—
Software		137,811		—
Bioreactors		1,280,728		—
Other		213,564		66,105
Total construction-in-progress	$	4,608,778	$	6,729,673

The Bioreactors, the laboratory space and equipment at Headquarters were placed into service at the end of March 2022.

Note 13 - Fair Value Measurements - Fair Value Assets and Liabilities Valuation Inputs (Details)	Dec. 31, 2021 $ / shares yr	Oct. 22, 2021 $ / shares yr
Measurement Input, Risk Free Interest Rate [Member]
Warrants, outstanding inputs	0.0124	0.0122
Measurement Input, Expected Term [Member]
Warrants, outstanding inputs \| yr	4.81	5.00
Measurement Input, Option Volatility [Member]
Warrants, outstanding inputs	0.430	0.255
Measurement Input, Share Price [Member]
Warrants, outstanding inputs \| $ / shares	7.81	8.44

Note 10 - Notes Payable - Schedule of Debt (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Total notes payable	$ 1,796,724	$ 710,768
Less: notes payable - current portion	1,796,724	538,731
Notes payable, noncurrent	0	172,037
Tractor Loan [Member]
Total notes payable	25,013	49,156
Paycheck Protection Program Loan [Member]
Total notes payable	0	661,612
Insurance Financing Note Payable [Member]
Total notes payable	$ 1,771,711	$ 0

Note 11 - Preferred Stock

12 Months Ended

Dec. 31, 2021

Preferred Stock [Text Block]

(11) Preferred Stock

On the Closing Date, pursuant to the Business Combination (as described in Note 4), 17,750,882 outstanding shares of Preferred Stock were automatically converted into 8,259,505 shares of common stock pursuant to the Exchange Ratio.

In addition, upon the closing of the Business Combination, pursuant to the terms of the Second Amended and Restated Certificate of Incorporation, the Company authorized 10,000,000 shares of preferred stock with a par value $0.0001.

Prior to the Business Combination, in August 2019, the Company’s Certificate of Incorporation was amended to authorize the Company to issue 50,000,000 shares of preferred stock, of which 6,615,000 shares were designated as Series A preferred stock, 2,525,800 shares were designated as series A- 1 preferred stock, 4,039,963 shares were designated as series A- 2 preferred stock, 3,333,333 shares were designated as series A- 2A preferred stock, and 8,571,429 shares were designated as series B preferred stock. The carrying value of Series A preferred stock was $1 per share, Series A- 1 $1.88 per share, Series A- 2 & A- 2A $3.00 per share, and Series B $3.50 per share.

The preferred stock was entitled to receive noncumulative dividends in preference to any dividend on the common stock when, as, and if declared by the Company’s board of directors. The holders of the preferred stock also were entitled to participate pro rata in any dividends paid on the common stock on an as-if-converted basis.

Each holder of preferred stock was entitled to the number of votes equal to the number of shares of common stock that it could be converted into. As long as there were 8,000,000 shares of preferred stock outstanding, the vote or written consent of the holder of the majority of the outstanding preferred stock (all series voting as a single class) was required to approve any amendment of the certificate of incorporation that changes voting, preferences or privileges or restrictions of the preferred stock.

In the event of liquidation or winding up of the Company, the preferred stockholders also were entitled to receive in preference to the holders of the common stock the greater of: a) a per share amount equal to their respective original purchase price plus any declared but unpaid dividends (the “Liquidation Preference”); or b) the amount to be paid on the common stock on an as-if-converted basis. The remaining assets would be distributed to the common stockholders.

The holders of preferred stock had the right to convert the preferred stock into common stock, at any time, utilizing the then- effective conversion rate. The effective conversion rate as of December 31, 2020 was 1:1. All preferred shares were automatically converted into common shares utilizing the then effective preferred conversion rate upon: a) the closing of the Company’s sale of its common stock in a firm commitment underwritten public offering pursuant to a registration statement under the Securities Act of 1933, covering the sale of the Company’s common stock if gross proceeds are at least $20,000,000 and the Company’s shares have been listed on a stock exchange, as defined; or b) the election of the holders of a majority of the outstanding shares of preferred stock.

With any change of control of the Company or financing, the preferred stockholders were to approve through majority vote any such change in control or financing event approved by the board of directors or the majority of the common stockholders. The preferred stock contained certain anti-dilution provisions, as defined.

In addition to the rights described above, series A- 2A preferred stock was redeemable at a price equal to $5 per preferred share at the option of the investor at any time during the redemption period, which was scheduled to commence in August 2022 and end in August 2023. As a result of the redemption feature, the Company classified the series A- 2A preferred stock as mezzanine equity as of January 1, 2020. However, the redemption feature was terminated during the year ended December 31, 2020, and the series A- 2A preferred stock was reclassified from mezzanine equity to permanent equity.

Note 13 - Fair Value Measurements - Fair Value of Assets and Liabilities Measured on Recurring Basis Gain (Loss) (Details) - Fair Value, Inputs, Level 3 [Member] - Fair Value, Recurring [Member]	12 Months Ended
	Dec. 31, 2021 USD ($)
Balance	$ 0
Initial measurement on the Closing Date	244,062
Change in fair value of Private Placement Warrant liability	183,568
Balance	$ 427,630

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2021	Oct. 22, 2021	Oct. 21, 2021	Dec. 31, 2020	Aug. 31, 2019
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, authorized (in shares)	10,000,000	10,000,000		10,000,000	50,000,000
Preferred stock, issued (in shares)	0			0
Preferred stock, outstanding (in shares)	0		17,750,882	0
Common stock, par value (in dollars per share)	$ 0.0001			$ 0.0001
Common stock, authorized (in shares)	490,000,000			490,000,000
Common stock, issued (in shares)	43,487,279			25,973,406
Common stock, outstanding (in shares)	43,487,279			25,973,406

Note 8 - Leases (Tables)

12 Months Ended

Dec. 31, 2021

Estimated Useful Lives Of Finance Lease Assets [Table Text Block]

Animal Facility	40 years
Equipment	3 - 7 years
Land	Indefinite

Schedule of Weighted Average Operating and Finance Leases [Table Text Block]

	*Operating*		*Finance*
Weighted-average remaining lease term	2.44 years		16.80 years
Weighted-average discount rate		4.58%		7.71%

Contractual Obligation, Fiscal Year Maturity [Table Text Block]

	*Operating*			*Finance*
2022	$	1,240,333		$	444,928
2023		1,169,559			406,339
2024		535,943			401,496
2025		—			401,496
2026		—			401,496
Thereafter		—			4,784,494
Undiscounted future minimum lease payments		2,945,835			6,840,249
Less: Amount representing interest payments		(150,237	)		(2,916,769	)
Total lease liabilities		2,795,598			3,923,480
Less current portion		(1,142,413	)		(161,050	)
Noncurrent lease liabilities	$	1,653,185		$	3,762,430

Note 2 - Summary of Significant Accounting Policies - Impact of Restatement (Details) (Parentheticals) - $ / shares	Dec. 31, 2021	Oct. 22, 2021	Oct. 21, 2021	Dec. 31, 2020	Aug. 31, 2019
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001	$ 0.0001		$ 0.0001
Preferred Stock, Shares Authorized (in shares)	10,000,000	10,000,000		10,000,000	50,000,000
Preferred stock, issued (in shares)	0			0
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	0		17,750,882	0
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001			$ 0.0001
Common stock, authorized (in shares)	490,000,000			490,000,000
Common stock, issued (in shares)	43,487,279			25,973,406
Common stock, outstanding (in shares)	43,487,279			25,973,406

Note 4 - Reverse Recapitalization and Business Combination - Schedule of Business Combination Reconciliations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Oct. 22, 2021	Dec. 31, 2019
Total	$ 34,340,225	$ 0
Plus: restricted cash - Forward Share Purchase Agreement	6,338,306	0
Less: forward share purchase liability assumed from BCYP			$ (24,838,085)
Total	38,549,913	$ 39,007,835		$ 7,694,433
Big Cypress Acquisition Corp [Member]
Cash - BCYP trust and cash, net of redemptions	22,535,723
Plus: restricted cash - Forward Share Purchase Agreement	13,098,599
Less: cash transaction costs allocated to the Company's equity	(1,294,097)
Total	34,340,225
Cash - BCYP trust and cash, net of redemptions	22,535,723
Less: non-cash net working capital assumed from BCYP	(5,067,682)
Less: fair value of redeemable warrants	(6,569,062)
Less: transaction costs allocated to the Company's equity	(3,294,096)
Total	7,604,883
Big Cypress Acquisition Corp [Member] \| Forward Share Purchase Agreement [Member]
Plus: restricted cash - Forward Share Purchase Agreement	13,098,599
Less: forward share purchase liability assumed from BCYP	$ (13,098,599)

Note 15 - Related Party Transactions (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Feb. 24, 2016	Feb. 14, 2016
Director [Member] \| Consulting Fees [Member]
Related Party Transaction, Amounts of Transaction	$ 25,000	$ 25,000
Board Member [Member] \| Board Member Fees [Member]
Related Party Transaction, Amounts of Transaction	6,250	6,250
Network Plus, LLC [Member] \| IT Assistance and Computer Setups [Member]
Related Party Transaction, Amounts of Transaction		19,000
Dakota Ag Investments [Member] \| Lease Payments [Member]
Related Party Transaction, Amounts of Transaction	435,000	401,000
Sanford Health [Member]
Accounts Payable, Related Parties (Deprecated 2023)	0	10,000
Sanford Health [Member] \| Lab Supply Payments [Member]
Related Party Transaction, Amounts of Transaction	$ 108,000	$ 152,000
Christiansen Land and Cattle, Ltd [Member] \| Line of Credit [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 3,000,000.0	$ 3,000,000.0

Note 19 -Subsequent Events

12 Months Ended

Dec. 31, 2021

Subsequent Events [Text Block]

(19) Subsequent Events

In January 2022, the Company received a final settlement notice related to the Forward Share Purchase Agreement. In conjunction with the final settlement, the Company repurchased 546,658 shares of common stock from Radcliffe at the Market Sales Price. The Company settled the repurchase with $5.5 million of the total $6.3 million held in restricted cash as of December 31, 2021, with the remaining balance of $0.8 million released to the Company. As a result of the final settlement transaction, the forward share purchase liability was reduced to zero.

On March 28, 2022, the Company entered into a Third Amendment to the Amended and Restated Lease Agreement with Sanford. The Third Amendment, among other things, provides for the least by the Company from Sanford of an additional 4,035 square feet of storage, laboratory and office space. The Third Amendment modifies the rent due under the Sanford Lease Agreement to $25.27 per square foot, or $841,061 due on an annual basis ( $70,088 due on a monthly basis), until increased pursuant to the terms of the Sanford Lease Agreement. The associated amendment was retroactively applied to October 2021, and accounted for under ASC 842 as a separate right-of-use asset. The consolidated financial statements and Note 8, Leases, include the relevant adjustments for the Third Amendment.

Note 8 - Leases - Schedule of Weighted Average Operating and Finance Leases (Details)	Dec. 31, 2021
Weighted-average remaining operating lease term (in years) (Year)	2 years 5 months 8 days
Weighted-average remaining finance lease term (in years) (Year)	16 years 9 months 18 days
Weighted-average operating discount rate	4.58%
Weighted-average finance discount rate	7.71%

Note 12 - Stock Option Plans

12 Months Ended

Dec. 31, 2021

Share-Based Payment Arrangement [Text Block]

(12) Stock Option Plans

On August 5, 2014, the Company approved a stock option grant plan (the “2014 Equity Incentive Plan”) for employees, directors, and non-employee consultants, which provides for the issuance of options to purchase common stock. The total shares authorized under the plan was originally 8,000,000; however, during 2019, the Plan was amended to increase the total shares authorized under the plan to 16,000,000. As a result of the Business Combination, the 2014 Equity Incentive Plan was amended to reduce the shares authorized to 7,444,800 based upon the impact of the Exchange Ratio.

As a result of the Business Combination, the Company adopted the 2021 Omnibus Equity Incentive Plan (hereinafter collectively with the 2014 Equity Incentive Plan referred to as the "Equity Compensation Plans"), representing 11,000,000 shares of common stock reserved for issuance upon exercise of stock options.

Vesting of the stock options is based upon years of service (employment). As of December 31, 2021 and 2020, 3,724,957 and 3,202,354 stock options, respectively, were vested and exercisable. During the year ended December 31, 2021, 12,500 of the vested options were exercised, while as of December 31, 2020, none of the vested stock options were exercised. As of December 31, 2021, the aggregate intrinsic value of stock options outstanding was $28.9 million, of which $4.1 million was unvested and $24.8 million was vested and exercisable.

The Company uses the Black Scholes model to estimate the fair value of the stock options granted. For stock options granted during the years ended December 31, 2021 and 2020, the Company utilized the following weighted-average assumptions: A risk free interest rate of 0.85% and 0.13%, respectively; expected term of 6.25 years (both years); expected dividend yield of 0% (both years); and a volatility factor of 92.8% and 106.1%, respectively. There were 328,718 forfeitures and zero expirations during the year ended December 31, 2021. There were no forfeitures or expirations during the year ended December 31, 2020.

The expected term of the stock options was estimated using the “simplified” method, as defined by the SEC’s Staff Accounting Bulletin No. 107, Share-Based Payment. The volatility assumption was determined by examining the historical volatilities for industry peer companies, as the Company does not have sufficient trading history for its common stock. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the options. The dividend assumption is based on the Company’s history and expectation of dividend payouts. The Company has never paid dividends on its common stock and does not anticipate paying dividends on its common stock in the foreseeable future. Therefore, the Company has assumed no dividend yield for purposes of estimating the fair value of the options.

Stock option activity for employees and non-employees under the Equity Compensation Plans for the years ended December 31, 2021 and 2020 was as follows:

	*Options*		*Weighted Average Fair Value*		*Weighted Average Exercise Price*
Balance, December 31, 2019		3,139,855	$	0.82	$	0.88
Granted		962,088	$	3.44	$	2.69
Balance, December 31, 2020		4,101,943	$	1.43	$	1.30
Granted		1,346,947	$	5.36	$	5.81
Forfeited		328,718	$	2.17	$	2.06
Exercised		12,500	$	0.39	$	0.54
Balance, December 31, 2021		5,107,672	$	2.30	$	2.44
Unvested at December 31, 2021		1,382,715	$	5.41	$	5.92
Vested and exercisable at December 31, 2021		3,724,957	$	1.14	$	1.16

Total unrecognized compensation cost related to non-vested stock options as of December 31, 2021 was approximately $6.6 million and is expected to be recognized within future operating results over a weighted-average period of 2.31 years. As of December 31, 2021, the weighted-average contractual term of the options outstanding was approximately 5.78 years. As of December 31, 2021, the weighted-average contractual term of the vested options was approximately 4.46 years. During the years ended December 31, 2021 and 2020, 461,701 shares and 400,632 shares, respectively, vested.

Stock-based compensation expense for the years ended December 31, 2021 and 2020 was as follows:

	*2021*		*2020*
Research and development	$	964,926	$	635,824
General and administrative		1,349,756		659,599
Total	$	2,314,682	$	1,295,423

Note 4 - Reverse Recapitalization and Business Combination

12 Months Ended

Dec. 31, 2021

Reverse Recapitalization and Business Combination [Text Block]

(4) Reverse Recapitalization and Business Combination

On the Closing Date, BCYP closed the Business Combination with SAB Biotherapeutics, as a result of which SAB Biotherapeutics became a wholly-owned subsidiary of BCYP. While BCYP was the legal acquirer of SAB Biotherapeutics in the Business Combination, for accounting purposes, the Business Combination is treated as a Reverse Recapitalization. SAB Biotherapeutics is treated as the accounting acquirer with historical financial statements of SAB Biotherapeutics becoming the historic financial statements of BCYP (renamed SAB Biotherapeutics, Inc.) upon consummation of the Business Combination. Under this method of accounting, BCYP is treated as the "acquired" company and SAB Biotherapeutics is treated as the acquirer for financial reporting purposes. For accounting reporting purposes, the Business Combination was treated as the equivalent of SAB Biotherapeutics issuing stock for the net assets of BCYP, accompanied by a recapitalization. The net assets of BCYP were stated at historical cost, with no goodwill or other intangible assets recorded.

Pursuant to the Business Combination Agreement, the aggregate consideration payable to stockholders of SAB Biotherapeutics at the Closing Date consisted of 36,465,343 shares of New SAB Biotherapeutics common stock, par value $0.0001 per share ("Common Stock"). Each option of SAB Biotherapeutics that was outstanding and unexercised immediately prior to the Effective Time (whether vested or unvested) was assumed by BCYP and converted into an option to acquire an adjusted number of shares of Common Stock at an adjusted exercise price per share, in each case, pursuant to the terms of the Business Combination Agreement (the "Rollover Options").

Additionally, the Business Combination Agreement included an earnout provision whereby the shareholders of SAB Biotherapeutics shall be entitled to receive additional consideration (“Earnout Shares”) if the Company meets certain Volume Weighted Average Price (“VWAP") thresholds, or a change in control with a per share price exceeding the VWAP thresholds within a five-year period immediately following the Closing.

The Earnout Shares shall be released in four equal increments as follows:

	(i)	25% of the Earnout Shares shall be released if, at any time during the five (5)-year period immediately following the Closing Date, the VWAP of the Company's publicly traded common stock is greater than or equal to $15.00 for any twenty (20) trading days within a period of thirty (30) consecutive trading days (the “First Earnout”).
	(ii)	25% of the Earnout Shares shall be released if, at any time during the five (5)-year period immediately following the Closing Date, the VWAP of the Company's publicly traded common stock is greater than or equal to $20.00 for any twenty (20) trading days within a period of thirty (30) consecutive trading days (the “Second Earnout”).
	(iii)	25% of the Earnout Shares shall be released if, at any time during the five (5)-year period immediately following the Closing Date, the VWAP of the Company's publicly traded common stock is greater than or equal to $25.00 for any twenty (20) trading days within a period of thirty (30) consecutive trading days (the “Third Earnout”).
	(iv)	25% of the Earnout Shares shall be released if, at any time during the five (5)-year period immediately following the Closing Date, the VWAP of the Company's publicly traded common stock is greater than or equal to $30.00 for any twenty (20) trading days within a period of thirty (30) consecutive trading days (the “Fourth Earnout” and together with the First Earnout, the Second Earnout and the Third Earnout, the “Earnouts”).

At the Effective Time, each outstanding share of SAB Biotherapeutics common stock, including shares of SAB Biotherapeutics common stock resulting from the conversion of outstanding shares of SAB Biotherapeutics preferred stock (as calculated pursuant to the SAB Biotherapeutics certificate of incorporation), immediately prior to the Effective Time, was converted into the right to receive a pro rata portion of the total consideration and the contingent right to receive a pro rata portion of the Earnout Shares.

Pursuant to the terms of the Business Combination Agreement, SAB Biotherapeutics’ securityholders (including vested option holders) who own SAB Biotherapeutics securities immediately prior to the Closing Date will have the contingent right to receive their pro rata portion of (i) an aggregate of 12,000,000 shares of Common Stock (“Earnout Shares”), of which 1,508,063 are contingently issuable based upon future satisfaction of the aforementioned VWAP thresholds. The remaining 10,491,937 are legally issued and outstanding, if the Company does not meet the above VWAP thresholds, or a change in control with a per share price below the VWAP thresholds occurs within a five-year period immediately following the Closing Date, the shares will be returned to the Company.

The Earnout Shares are indexed to our equity and meet the criteria for equity classification. On the Closing Date, the fair value of the 12,000,000 Earnout Shares was $101.3 million. We reflected the Earnout Shares in the consolidated balance sheet at December 31, 2021 as a stock dividend by reducing additional paid-in capital, which was offset by the increase in additional paid-in capital associated with the Business Combination.

Preceding the Business Combination, on October 12, 2021, BCYP entered into a Forward Share Purchase Agreement (the “Forward Share Purchase Agreement”) with Radcliffe SPAC Master Fund, L.P., a Cayman Islands exempted limited partnership (“Radcliffe”). Under the Forward Share Purchase Agreement, Radcliffe shall sell and transfer to BCYP, and BCYP shall purchase from Radcliffe, up to 1,390,000 shares of common stock owned by Radcliffe at the closing of the Business Combination at a per Share price (the “Purchase Price”) equal to $10.10 per share (the "Market Sales Price"). Further, BCYP shall purchase the remaining shares held by Radcliffe not sold in the open market in excess of the Market Sales Price at the later of (a) the 90th day after the closing of the Business Combination, or (b) the first business day following the 95th day after the closing of the Business Combination if BCYP directs Radcliffe to sell shares at a mutually agreed upon price other than the Market Sales Price. As of the Closing Date, 1,296,891 shares of common stock were held by Radcliffe under the Forward Share Purchase Agreement.

Pursuant to the treatment of the Business Combination as a reverse recapitalization, SAB Biotherapeutics assumed the liability position as it existed as of the Effective Time. The net assets of the acquired entity were adjusted to include a forward share purchase liability of $13,098,599. In connection with the Business Combination, an amount matching the assumed forward share purchase liability was transferred into escrow, pending final settlement of the Forward Share Purchase Agreement in January 2022. Given the short-term nature of the Forward Share Purchase Agreement, the Company did not present value the forward share purchase liability. Subsequent settlements whereby Radcliffe sold shares in the open market in excess of the Market Sales Price were treated as a reduction in the assumed forward share purchase liability, with an offsetting increase in equity of the Company. Prior to December 31, 2021, a portion of the forward share purchase liability was settled. As of December 31, 2021, the forward share purchase liability balance was $6,338,306 on the consolidated balance sheet.

The following table reconciles the elements of the Business Combination to the consolidated statement of cash flows for the year ended December 31, 2021:

	*Recapitalization*
Cash - BCYP trust and cash, net of redemptions	$	22,535,723
Plus: restricted cash - Forward Share Purchase Agreement		13,098,599
Less: cash transaction costs allocated to the Company's equity		(1,294,097	)
Total	$	34,340,225

The following table reconciles the elements of the Business Combination to the consolidated statement of changes in redeemable preferred stock and stockholders' equity (deficit) for the year ended December 31, 2021:

	*Recapitalization*
Cash - BCYP trust and cash, net of redemptions	$	22,535,723
Plus: restricted cash - Forward Share Purchase Agreement		13,098,599
Less: non-cash net working capital assumed from BCYP		(5,067,682	)
Less: forward share purchase liability assumed from BCYP		(13,098,599	)
Less: fair value of redeemable warrants		(6,569,062	)
Less: transaction costs allocated to the Company's equity		(3,294,096	)
Total	$	7,604,883

The following table details the number of shares of common stock issued immediately following the consummation of the Business Combination:

	*Shares*
Common stock, reedeemable and outstanding prior to Business Combination		11,500,000
Less: redemption of BCYP shares		(8,030,289	)
Common stock of BCYP		3,469,711
BCYP Founder and private shares		3,292,200
Shares issued for services		247,525
Total BCYP shares		7,009,436
SAB Biotherapeutics, Inc and subsidiaries shareholders		36,465,343
Total shares of common stock immediately after Business Combination		43,474,779

The following table details the allocated assets acquired and liabilities assumed as follows:

Assets Acquired
BCYP trust and cash, net of redemptions	$	22,535,723
Restricted cash - Forward Share Purchase Agreement		13,098,599
Other assets		102,742
Assets acquired	$	35,737,064
Liabilities Assumed
Forward share purchase liability	$	13,098,599
Fair value of redeemable warrants		6,569,062
Other liabilities and accrued expenses		5,170,424
Liabilities assumed		24,838,085
Net Assets Acquired	$	10,898,979

Note 8 - Leases - Estimated Useful Lives of Finance Lease Assets (Details)	12 Months Ended
	Dec. 31, 2021
Estimated useful life (Year)	3 years
Animal Facility [Member]
Estimated useful life (Year)	40 years
Equipment [Member] \| Minimum [Member]
Estimated useful life (Year)	3 years
Equipment [Member] \| Maximum [Member]
Estimated useful life (Year)	7 years

Note 15 - Related Party Transactions

12 Months Ended

Dec. 31, 2021

(15) Related Party Transactions

For the years ended December 31, 2021 and 2020, the Company paid consulting fees to a board member, Christine Hamilton, who is also an owner, of $25,000 and $25,000, respectively. As of December 31, 2021 and 2020, there was $6,250 (both years) in accrued board member fees for this related party.

For the year ended December 31, 2020, the Company paid Network Plus, LLC (owner is the spouse of an employee) approximately $19,000 for IT assistance and computer setups. The spouse became an employee of the Company in July 2020, and there was no further activity with this vendor.

For the years ended December 31, 2021 and 2020, the Company made lease payments to Dakota Ag Properties of $435,000 and $401,000, respectively. Dakota Ag Investments (part of Dakota Ag Properties) is a shareholder and owner of the Company.

For the years ended December 31, 2021 and 2020, not including lease payments, the Company made lab supply payments to Sanford Health (which is a shareholder of the Company) totaling approximately $108,000 and $152,000, respectively. The Company had no related party payables with Sanford Health as of December 31, 2021, and $10,000 of related party payables with Sanford Health as of December 31, 2020.

As discussed in Note 10, Notes Payable, on February 24, 2016, the Company entered into a loan agreement with CLC for a $3.0 million revolving line of credit secured by a blanket security interest in the assets of the Company. The principal owners of CLC are owners, members of the board of directors, and former employees of the Company. In July 2020, the note payable was paid in full. Please refer to Note 10, Notes Payable, for additional information.

Note 7 - Equipment (Tables)

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Table Text Block]

	*2021*		*2020*
Laboratory equipment	$	7,431,988	$	5,205,346
Animal facility		8,357,667		3,371,125
Animal facility equipment		1,253,879		1,003,629
Construction-in-progress		4,608,778		6,729,673
Leasehold improvements		5,700,364		185,971
Vehicles		135,593		96,693
Office furniture and equipment		46,202		20,219
Less: accumulated depreciation and amortization		3,220,016		1,767,186
Property, plant and equipment net	$	24,314,455	$	14,845,470

Construction In Progress [Table Text Block]

	*2021*		*2020*
200L commercial facility	$	—	$	4,148,113
200L commercial facility equipment		—		486,381
New animal barn (#6)		—		1,551,167
New office space (at Headquarters)		11,183		477,907
Laboratory space at Headquarters		2,506,482		—
Lab equipment at Headquarters		246,801		—
IT equipment for new office space		212,209		—
Software		137,811		—
Bioreactors		1,280,728		—
Other		213,564		66,105
Total construction-in-progress	$	4,608,778	$	6,729,673

Note 10 - Notes Payable (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Debt [Table Text Block]

	*2021 (Restated)*		*2020*
Tractor loan	$	25,013	$	49,156
PPP loan		—		661,612
Insurance financing note payable		1,771,711		—
Total notes payable		1,796,724		710,768
Less: notes payable - current portion		1,796,724		538,731
Notes payable, noncurrent	$	—	$	172,037

Note 6 - Earnings Per Share - Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share (Details)

12 Months Ended

Dec. 31, 2021

Share-Based Payment Arrangement, Option [Member]

21,683,557

3,724,957

Warrant [Member]

5,958,600

Earnout Shares [Member]

Contingently Issuable Earnout Shares From Unexercised Rollover Options [Member]

10,491,937

^[1]

1,508,063

[1]	As the Earnout shares are subject to certain vesting requirements not satisfied as of the year ended December 31, 2021, the Earnout Shares held in escrow are excluded from calculating both basic and diluted earnings per share.

Note 14 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	*2021*			*2020*
Deferred tax assets:
Net operating loss carryforwards	$	5,078,429		$	2,659,082
Stock-based compensation		1,156,235			600,592
Vacation accrual		99,300			84,553
Lease liabilities		623,286			727,587
Other accrued expenses		1,119,721			—
Start-up costs		297,136			—
Total deferred tax assets	$	8,374,107		$	4,071,814
Less valuation allowance		(5,300,689	)		(2,320,958	)
Total deferred tax assets after valuation allowance		3,073,418			1,750,856
Deferred tax liabilities:
Operating lease right-of-use asset		551,547			641,135
Depreciation and amortization		2,521,871			1,109,721
Total deferred tax liabilities		3,073,418			1,750,856
Net deferred tax asset (liability)	$	—		$	—

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	*2021*					*2020*
Rate reconciliation:
Net (loss) income before tax	$	(17,144,531	)			$	20,117,773
Federal income tax at statutory rate		(3,600,352	)	21.00	%		4,224,732		21.00	%
State income tax		(9,849	)	0.06	%		—		—	%
Permanent items		1,029,874		(6.01	)%		918		(0.01	)%
Valuation allowance		2,679,238		(15.63	)%		(4,225,651	)	(20.99	)%
Other		(98,911	)	0.58	%		1		—	%
	$	—		—	%	$	—		—	%

Note 14 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
Note 14 - Income Taxes (Details Textual) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%	21.00%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 2,980,000	$ (4,226,000)
Unrecognized Tax Benefits, Ending Balance	0	0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total	0	0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0	$ 0
Domestic Tax Authority [Member] \| Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards	$ 25,175,483

Note 5 - Revenue

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Text Block]

(5) Revenue

During the years ended December 31, 2021 and 2020, the Company worked on the following grants:

Government grants

The total revenue for government grants was approximately $60.9 million and $52.8 million respectively, for the years ended December 31, 2021 and 2020.

National Institute of Health – National Institute of Allergy and Infectious Disease (“NIH-NIAID”) (Federal Award #1R44AI117976- 01A1) – this grant was for $1.4 million and started in September 2019 through August 2021. For the years ended December 31, 2021 and 2020, there was approximately $518,000 and $228,000, respectively, in grant income recognized. The corporation applied for an extension on the grant funding, and the extension is pending approval. If approved, there is approximately $203,000 in funding remaining for this grant as of December 31, 2021.

NIH-NIAID (Federal Award #1R41AI131823- 02) – this grant was for approximately $1.5 million and started in April 2019 through March 2021. The grant was subsequently amended to extend the date through March 2022. For the years ended December 31, 2021 and 2020, there was approximately $51,000 and $99,000 respectively, in grant income recognized. There is approximately $823,000 in funding remaining for this grant as of December 31, 2021.

NIH-NIAID through Geneva Foundation (Federal Award #1R01AI132313- 01, Subaward #S- 10511- 01) – this grant was for approximately $2.7 million and started in August 2017 through July 2021. For the years ended December 31, 2021 and 2020, there was approximately $94,000 and $351,000, respectively, in grant income recognized from this grant. The corporation applied for an extension on the grant funding, and the extension is pending approval. If approved, there is approximately $1.5 million in funding remaining for this grant as of December 31, 2021.

Department of Defense, Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense Enabling Biotechnologies (“JPEO”) through Advanced Technology International – this grant was for a potential of $25 million, awarded in stages starting in August 2019 and with potential stages running through February 2023. Additional contract modifications were added to this contract in 2020 and 2021 for work on a COVID therapeutic, bringing the contract total to $204 million. For the years ended December 31, 2021 and 2020, there was approximately $60.2 million and $52.1 million, respectively, in grant income recognized from this grant. There is approximately $89.2 million in funding remaining for this grant as of December 31, 2021.

The grants for the JPEO contract are cost reimbursement agreements, with reimbursement of our direct research and development expense (labor and consumables) with an overhead charge (based on actual, reviewed quarterly) and a fixed fee ( 9%). However, a portion of the funding ( $12 million in 2020) from this contract was for capacity building, including funding for equipment and facilities. A majority of this was for a 200L purification suite and two production barns, which are in locations that are currently leased by the corporation. While the government and the Company have agreed to negotiate in good faith to afford government access to this equipment, the Company is allowed to use this equipment for any project. As a majority of the value is in leasehold improvements (and therefore cannot be returned to the government), the corporation is treating the assets as company owned, and recognized the proceeds from the reimbursement as revenue. Therefore, revenue significantly exceeded research and development expenses, as there were no research and development expenses to offset the $12 million in revenue.

Other grants (non-government)

The total revenue for other grants (non-government) was approximately $0 and $2.4 million for the years ended December 31, 2021 and 2020, respectively.

CSL Behring – there were three contracts for a combined $2.4 million that were started and completed in 2020. These contracts were related to research and development for a COVID- 19 therapeutic ( $2 million) and two other targets ( $400,000).

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI https://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ / shares in Units, $ in Thousands		12 Months Ended
	Oct. 22, 2021 $ / shares shares	Dec. 31, 2021 USD ($) $ / shares	Dec. 31, 2020 USD ($) $ / shares	Dec. 31, 2022
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares		$ 0.0001	$ 0.0001
Preferred Stock, Convertible, Conversion Ratio				1
Accounts Receivable, Allowance for Credit Loss, Writeoff		$ 0	$ 0
Accounts Receivable, Allowance for Credit Loss		0	0
Asset Impairment Charges, Total		$ 0	$ 0
Number of Reportable Segments		1
Contract Research Organizations [Member]
Research and Development Agreement, Good Standing Percentage		90.00%
HVIVI Services [Member]
Research and Development Agreement, Good Standing Percentage		90.00%
Revenue from Contract with Customer Benchmark [Member] \| Customer Concentration Risk [Member] \| Government Organization Grants [Member]
Concentration Risk, Percentage		100.00%	96.00%
Revenue from Contract with Customer Benchmark [Member] \| Customer Concentration Risk [Member] \| Non Government [Member]
Concentration Risk, Percentage		0.00%	4.00%
Big Cypress Acquisition Corp [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares	$ 0.0001
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) \| shares	1
Preferred Stock, Convertible, Conversion Ratio	0.4653
Sale of Stock, Number of Shares Issued in Transaction (in shares) \| shares	36,465,343

Note 2 - Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Significant Accounting Policies [Text Block]

(2) Summary of Significant Accounting Policies

A summary of the significant accounting policies applied in preparation of the accompanying consolidated financial statements is set forth below.

Restatement of Previously issued Financial Statements

In March 2023, the Audit Committee of the Company’s Board of Directors and the Company’s management concluded that the Company’s previously issued audited financial statements contained within the Annual Report on Form 10-K for the year ended December 31, 2021
should no longer be relied upon as a result of the following accounting errors:

●

The Company concluded that it did not correctly account for a financed insurance premium whereby a third-party lender prepaid the Company's annual insurance premiums to our insurance companies in exchange for a short-term interest bearing note (the “Insurance Financing Agreement”). The Company previously recognized, on its consolidated balance sheet, a current prepaid asset for the amount paid by the Company under the Insurance Financing Agreement in excess of the total amortized value of the prepaid insurance policy. The Company reassessed its accounting for the Insurance Financing Agreement and determined that the Insurance Financing Agreement should be classified as a current note payable with the full amount of the insurance premium recognized as current prepaid asset at the time the Company entered into the Insurance Financing Agreement.

●

The Company concluded that the Insurance Financing Agreement and corresponding payment to the third-party lender constitutes a constructive receipt and disbursement of cash. As a result, the Company determined the cash flows from financing activities contained within the Annual Report on Form 10-K for the year ended December 31, 2021 is understated—this error is accompanied by a corresponding overstatement in cash flows from operating activities due to an understated prepaid asset.

Impact of the Restatement

The Company has restated herein its audited financial statements for the year ended December 31, 2021.

December 31, 2021

As Previously Reported

Adjustment

As Restated

Assets

Current assets

Cash and cash equivalents
$ 33,206,712 $ — $ 33,206,712

Restricted cash
6,338,306 — 6,338,306

Accounts receivable, net
8,010,708 — 8,010,708

Prepaid expenses
864,513 1,771,711 2,636,224

Total current assets
48,420,239 1,771,711 50,191,950

Operating lease right-of-use assets
2,615,204 — 2,615,204

Financing lease right-of-use assets
4,019,322 — 4,019,322

Equipment, net
24,314,455 — 24,314,455

Total assets
$ 79,369,220 $ 1,771,711 $ 81,140,931

Liabilities and Stockholders’ Equity

Current liabilities

Accounts payable
$ 4,458,525 $ — $ 4,458,525

Forward share purchase liability
6,338,306 — 6,338,306

Notes payable – current portion
25,013 1,771,711 1,796,724

Operating lease liabilities, current portion
1,142,413 — 1,142,413

Finance lease liabilities, current portion
161,050 — 161,050

Due to related party
2,367 — 2,367

Deferred grant income
100,000 — 100,000

Accrued expenses and other current liabilities
12,455,888 — 12,455,888

Total current liabilities
24,683,562 1,771,711 26,455,273

Operating lease liabilities, noncurrent
1,653,185 — 1,653,185

Finance lease liabilities, noncurrent
3,762,430 — 3,762,430

Warrant liabilities
10,720,130 — 10,720,130

Notes payable, noncurrent
— — —

Total liabilities
40,819,307 1,771,711 42,591,018

Commitments and contingencies (Note 17)

Stockholders’ equity

Preferred stock; $0.0001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding at December 31, 2021 and 2020
— — —

Common stock; $0.0001 par value; 490,000,000 shares authorized at December 31, 2021 and 2020; 43,487,279 and 25,973,406 shares issued and outstanding at December 31, 2021 and 2020, respectively
4,349 — 4,349

Additional paid-in capital
67,674,515 — 67,674,515

Accumulated deficit
(29,128,951 ) — (29,128,951 )

Total stockholders’ equity
38,549,913 — 38,549,913

Total liabilities and stockholders’ equity
$ 79,369,220 $ 1,771,711 $ 81,140,931

Year Ended December 31, 2021

As Previously Reported

Adjustment

As Restated

Cash flows from operating activities:

Net (loss) income
$ (17,144,531 ) $ — $ (17,144,531 )

Adjustments to reconcile net (loss) income to net cash provided by operating activities:

Gain on debt extinguishment of Paycheck Protection Program SBA Loan
(665,596 ) — (665,596 )

Depreciation and amortization
1,488,614 — 1,488,614

Amortization of right-of-use assets
164,983 — 164,983

Stock-based compensation expense
2,314,682 — 2,314,682

Gain on sale of equipment
(5,488 ) — (5,488 )

Changes in fair value of warrant liabilities
4,151,068 — 4,151,068

Changes in operating assets and liabilities

Accounts receivable
12,558,790 — 12,558,790

Prepaid expenses
513,363 (1,771,711 ) (1,258,348 )

Right-of-use assets – operating lease
(63,626 ) — (63,626 )

Accounts payable
(2,935,521 ) — (2,935,521 )

Deferred income
— — —

Due to related party
(2,727 ) — (2,727 )

Accrued expense and other current liabilities
3,384,573 — 3,384,573

Net cash provided by operating activities
3,758,584 (1,771,711 ) 1,986,873

Cash flows from investing activities:

Proceeds from the sale of equipment
— — —

Purchases of equipment
(10,943,657 ) — (10,943,657 )

Net cash used in investing activities
(10,943,657 ) — (10,943,657 )

Cash flows from financing activities:

Proceeds from Business Combination, net of transaction costs
34,340,225 — 34,340,225

Proceeds from issuance of notes payable
— 2,840,619 2,840,619

Payments of notes payable
(24,143 ) (1,068,908 ) (1,093,051 )

Principal payments on finance leases
(203,124 ) — (203,124 )

Proceeds from exercise of stock options
6,750 — 6,750

Net cash provided by financing activities
34,119,708 1,771,711 35,891,419

Net increase in cash, cash equivalents, and restricted cash
26,934,635 — 26,934,635

Cash, cash equivalents, and restricted cash

Beginning of year
12,610,383 — 12,610,383

End of year
$ 39,545,018 $ — $ 39,545,018

A summary of the significant accounting policies applied in preparation of the accompanying consolidated financial statements is set forth below.

Basis of presentation

The financial statements have been prepared in conformity with U.S. Generally Accepted Accounting Principles ("GAAP") and include all adjustments necessary for the fair presentation of the Company’s financial position for the years presented.

The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, BCYP is treated as the “acquired” company and SAB Biotherapeutics is treated as the acquirer for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of SAB Biotherapeutics issuing stock for the net assets of BCYP, accompanied by a recapitalization. The net assets of BCYP are stated at historical cost, with no goodwill or other intangible assets recorded. SAB Biotherapeutics was determined to be the accounting acquirer based on the following predominant factors:

●

SAB Biotherapeutics’ shareholders have the largest portion of voting rights in the Company

●

the Board and Management are primarily composed of individuals associated with SAB Biotherapeutics;

●

the operations of SAB comprise the ongoing operations of the Company.

The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of SAB Biotherapeutics. At the Closing Date, and subject to the terms and conditions of the Merger Agreement, each share of SAB Biotherapeutics common stock, par value $0.0001 per share, and each share of the SAB Biotherapeutics convertible preferred stock that was convertible into a share of SAB Biotherapeutics common stock at a one-to- one ratio, was converted into Common Stock equal to 0.4653 (the "Exchange Ratio"). The shares and corresponding capital amounts and losses per share, prior to the Business Combination, have been retroactively restated based on shares reflecting the Exchange Ratio established in the Business Combination.

Emerging growth company status

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)( 1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Principles of consolidation

The accompanying consolidated financial statements include the results of the Company and its wholly owned subsidiaries, SAB Capra, LLC and Aurochs, LLC. Intercompany balances and transactions have been eliminated in consolidation.

Significant risks and uncertainties

The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, the results of research and development efforts, clinical trial activities of the Company’s product candidates, the Company’s ability to obtain regulatory approval to market its product candidates, competition from products manufactured and sold or being developed by other companies, and the Company’s ability to raise capital.

The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and obtaining and protecting intellectual property.

Funding from government grants is not guaranteed to cover all costs, and additional funding may be needed to cover operational costs as the Company moves forward to with our efforts to develop a commercially approved product.

Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the financial statements. The Company has used significant estimates in its determination of stock-based compensation assumptions, determination of the fair value of the Company’s common stock, determination of the fair value of the Private Placement Warrant liabilities, determination of the incremental borrowing rate (“IBR”) used in the calculation of the Company’s right of use assets and lease liabilities, and the valuation allowance on deferred tax assets. Actual amounts realized may differ from these estimates.

Cash, cash equivalents, and restricted cash

Cash equivalents include short-term, highly liquid instruments, consisting of money market accounts and short-term investments with original maturities at the date of purchase of 90 days or less.

Amounts held in escrow by the Company pursuant to the Forward Share Purchase Agreement were reported as restricted cash on the consolidated balance sheet as of December 31, 2021.

The reconciliation of cash, cash equivalents, and restricted cash as of the years ended December 31, 2021 and 2020 was as follows:

December 31, 2021

December 31, 2020

Cash and cash equivalents
$ 33,206,712 $ 12,610,383

Restricted cash
6,338,306 —

Total cash, cash equivalents, and restricted cash shown in the statement of cash flows
$ 39,545,018 $ 12,610,383

Accounts receivable

Accounts receivable are carried at original invoice amount, less an allowance for doubtful accounts. The Company estimates an allowance for doubtful accounts for potential credit losses that are expected to be incurred, based on management’s assessment of the collectability of specific accounts, the aging of the accounts receivable, historical information and other currently available evidence. Receivables are written off when deemed uncollectible. To date, no receivables have been written off. The Company had no allowance for doubtful accounts as of December 31, 2021 and 2020.

Concentration of credit risk

The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to credit risk is reduced by placing such deposits in high credit quality federally insured financial institutions.

The Company received 100% and approximately 96% of its total revenue through grants from government organizations during the years ended December 31, 2021 and 2020, respectively, and 0% and approximately 4% of its total revenue through a grant from a non-government organization during the years ended December 31, 2021 and 2020, respectively.

Lease liabilities and right-of-use assets

The Company is party to certain contractual arrangements for equipment, lab space, and an animal facility, which meet the definition of leases under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 842, Leases (“ASC 842”). In accordance with ASC 842, the Company recorded right-of-use assets and related lease liabilities for the present value of the lease payments over the lease terms. The Company’s IBR was used in the calculation of its right-of-use assets and lease liabilities.

Research and development expenses

Expenses incurred in connection with research and development activities are expensed as incurred. These include licensing fees to use certain technology in the Company’s research and development projects, fees paid to consultants and various entities that perform certain research and testing on behalf of the Company, and expenses related to salaries, benefits, and stock-based compensation granted to employees in research and development functions.

During the years ended December 31, 2021 and 2020, the Company had contracts with multiple contract research organizations (“CRO”) to complete studies as part of research grant agreements. In the case of SAB- 185, the CRO has been contracted and paid by the US government. For SAB- 176, PPD Development, LP acting as the CRO oversaw the Phase 1 safety study. The terms of that agreement are subject to confidentiality, and the status of the agreement is that it is current, in good standing and approximately 90% of the contract has been paid as of December 31, 2021. SAB has also contracted with hVIVO Services Limited to conduct the Phase 2a influenza study on SAB- 176. The terms of that agreement are subject to confidentiality, and the status of the agreement is that it is current, in good standing and approximately 90% of the contract has been paid as of December 31, 2021.

Equipment

The Company records equipment at cost less depreciation. Depreciation is calculated using straight-line methods over the following estimated useful lives:

(in years)

Animal facility equipment
7

Laboratory equipment
7

Leasehold improvements

Shorter of asset life or lease term

Office furniture & equipment
5

Vehicles
5

Repairs and maintenance expenses are expensed as incurred.

Impairment of long-lived assets

The Company reviews the recoverability of long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. If necessary, the Company compares the estimated undiscounted future net cash flows to the related asset’s carrying value to determine whether there has been an impairment. If an asset is considered impaired, the asset is written down to fair value, which is based either on discounted cash flows or appraised values in the period the impairment becomes known. The Company believes that long-lived assets are recoverable, and no impairment was deemed necessary, during the years ended December 31, 2021 and 2020.

Stock-based compensation

FASB ASC Topic 718, Compensation – Stock Compensation, prescribes accounting and reporting standards for all share-based payment transactions in which employee and non-employee services are acquired. The Company recognizes compensation cost relating to stock-based payment transactions using a fair-value measurement method, which requires all stock-based payments to employees, directors, and non-employee consultants, including grants of stock options, to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. Prior to the Business Combination, the grant date fair value of the Company's common stock was typically be determined by the Company's board of directors with the assistance of management and a third-party valuation specialist.

Subsequent to the Business Combination, the board of directors elected to determine the fair value of our post-merger common stock based on the closing market price at closing on the date of grant. In determining the fair value of stock-based awards, the Company utilizes the Black-Scholes option-pricing model, which uses both historical and current market data to estimate fair value. The Black-Scholes option-pricing model incorporates various assumptions, such as the value of the underlying common stock, the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. No awards may have a term in excess of ten years. Forfeitures are recorded when they occur. Stock-based compensation expense is classified in the consolidated statements of operations based on the function to which the related services are provided. The company recognizes stock-based compensation expense over the expected term.

Income taxes

Deferred income taxes reflect future tax effects of temporary differences between the tax and financial reporting basis of the Company’s assets and liabilities measured using enacted tax laws and statutory tax rates applicable to the periods when the temporary differences will affect taxable income. When necessary, deferred tax assets are reduced by a valuation allowance, to reflect realizable value, and all deferred tax balances are reported as long-term on the consolidated balance sheet. Accruals are maintained for uncertain tax positions, as necessary.

The Company uses a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The Company has elected to treat interest and penalties related to income taxes, to the extent they arise, as a component of income taxes.

Revenue recognition

The Company’s revenue is primarily generated through grants from government and other (non-government) organizations.

Grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606, Revenue from Contracts with Customers, as the organizations providing the grants do not meet the definition of a customer. Expenses for grants are tracked by using a project code specific to the grant, and the employees also track hours worked by using the project code.

Comprehensive income (loss)

The Company had no items of comprehensive income (loss) other than its net income (loss).

Litigation

From time to time, the Company is involved in legal proceedings, investigations and claims generally incidental to its normal business activities. In accordance with U.S. GAAP, the Company accrues for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal costs in connection with loss contingencies are expensed as incurred.

Earnings per share

On the Closing Date, the Company completed the Business Combination with BCYP, whereby the Company received 36,465,343 shares in exchange for all of its share capital. The effect of the Business Combination was reflected retroactively to January 1, 2020 and will be utilized for the calculation of earnings per share in all prior periods. The per share amounts have been updated to show the effect of the Exchange Ratio on earnings per share as if the exchange occurred at the beginning of both years for the consolidated financial statements of the Company. The impact of the stock exchange is also shown on the Company’s statements of changes in redeemable preferred stock and stockholders' equity (deficit).

In accordance with ASC 260, Earnings per Share (“ASC 260”), basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of common stock outstanding during the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted-average number of common stock outstanding for the period including potential dilutive common shares such as stock options.

Segment reporting

In accordance with ASC 280, Segment Reporting, the Company’s business activities are organized into one reportable segment, as only the Company’s operating results in their entirety are regularly reviewed by the Company’s chief operating decision maker to make decisions about resources to be allocated and to assess performance.

Common stock valuations

Prior to the Business Combination, the Company was required to periodically estimate the fair value of its common stock with the assistance of an independent third-party valuation firm, as discussed above, when issuing stock options and computing estimated stock-based compensation expense. The assumptions underlying these valuations represented the Company's best estimates, which involved inherent uncertainties and the application of significant levels of judgment. In order to determine the fair value of its common stock, the Company considered, among other items, previous transactions involving the sale of our securities, our business, financial condition and results of operations, economic and industry trends, the market performance of comparable publicly traded companies, and the lack of marketability of our common stock.

Subsequent to the Business Combination, the Company now determines the fair value of common stock based on the closing market price at closing on the date of grant.

Compensation expense related to stock-based transactions is measured and recognized in the financial statements at fair value of the post-merger common stock based on the closing market price at closing on the date of grant. Stock-based compensation expense is measured at the grant date based on the fair value of the equity award and is recognized as expense over the requisite service period, which is generally the vesting period, on the straight-line method. The Company estimates the fair value of each stock option award on the date of grant using the Black-Scholes option-pricing model. Determining the fair value of stock option awards at the grant date requires judgment, including estimating the expected volatility, expected term, risk-free interest rate, and expected dividends.

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Restatement of Previously Issued Financial Statement [Policy Text Block]

Restatement of Previously issued Financial Statements

In March 2023, the Audit Committee of the Company’s Board of Directors and the Company’s management concluded that the Company’s previously issued audited financial statements contained within the Annual Report on Form 10-K for the year ended December 31, 2021

should no longer be relied upon as a result of the following accounting errors:

●

The Company concluded that it did not correctly account for a financed insurance premium whereby a third-party lender prepaid the Company's annual insurance premiums to our insurance companies in exchange for a short-term interest bearing note (the “Insurance Financing Agreement”). The Company previously recognized, on its consolidated balance sheet, a current prepaid asset for the amount paid by the Company under the Insurance Financing Agreement in excess of the total amortized value of the prepaid insurance policy. The Company reassessed its accounting for the Insurance Financing Agreement and determined that the Insurance Financing Agreement should be classified as a current note payable with the full amount of the insurance premium recognized as current prepaid asset at the time the Company entered into the Insurance Financing Agreement.

●

The Company concluded that the Insurance Financing Agreement and corresponding payment to the third-party lender constitutes a constructive receipt and disbursement of cash. As a result, the Company determined the cash flows from financing activities contained within the Annual Report on Form 10-K for the year ended December 31, 2021 is understated—this error is accompanied by a corresponding overstatement in cash flows from operating activities due to an understated prepaid asset.

Impact of the Restatement

The Company has restated herein its audited financial statements for the year ended December 31, 2021.

	December 31, 2021
	As Previously Reported			Adjustment		As Restated
Assets
Current assets
Cash and cash equivalents	$	33,206,712		$	—	$	33,206,712
Restricted cash		6,338,306			—		6,338,306
Accounts receivable, net		8,010,708			—		8,010,708
Prepaid expenses		864,513			1,771,711		2,636,224
Total current assets		48,420,239			1,771,711		50,191,950
Operating lease right-of-use assets		2,615,204			—		2,615,204
Financing lease right-of-use assets		4,019,322			—		4,019,322
Equipment, net		24,314,455			—		24,314,455
Total assets	$	79,369,220		$	1,771,711	$	81,140,931
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable	$	4,458,525		$	—	$	4,458,525
Forward share purchase liability		6,338,306			—		6,338,306
Notes payable – current portion		25,013			1,771,711		1,796,724
Operating lease liabilities, current portion		1,142,413			—		1,142,413
Finance lease liabilities, current portion		161,050			—		161,050
Due to related party		2,367			—		2,367
Deferred grant income		100,000			—		100,000
Accrued expenses and other current liabilities		12,455,888			—		12,455,888
Total current liabilities		24,683,562			1,771,711		26,455,273
Operating lease liabilities, noncurrent		1,653,185			—		1,653,185
Finance lease liabilities, noncurrent		3,762,430			—		3,762,430
Warrant liabilities		10,720,130			—		10,720,130
Notes payable, noncurrent		—			—		—
Total liabilities		40,819,307			1,771,711		42,591,018
Commitments and contingencies (Note 17)
Stockholders’ equity
Preferred stock; $0.0001 par value; 10,000,000 shares authorized, 0 shares issued and outstanding at December 31, 2021 and 2020		—			—		—
Common stock; $0.0001 par value; 490,000,000 shares authorized at December 31, 2021 and 2020; 43,487,279 and 25,973,406 shares issued and outstanding at December 31, 2021 and 2020, respectively		4,349			—		4,349
Additional paid-in capital		67,674,515			—		67,674,515
Accumulated deficit		(29,128,951	)		—		(29,128,951	)
Total stockholders’ equity		38,549,913			—		38,549,913
Total liabilities and stockholders’ equity	$	79,369,220		$	1,771,711	$	81,140,931

	Year Ended December 31, 2021
	As Previously Reported			Adjustment			As Restated
Cash flows from operating activities:
Net (loss) income	$	(17,144,531	)	$	—		$	(17,144,531	)
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Gain on debt extinguishment of Paycheck Protection Program SBA Loan		(665,596	)		—			(665,596	)
Depreciation and amortization		1,488,614			—			1,488,614
Amortization of right-of-use assets		164,983			—			164,983
Stock-based compensation expense		2,314,682			—			2,314,682
Gain on sale of equipment		(5,488	)		—			(5,488	)
Changes in fair value of warrant liabilities		4,151,068			—			4,151,068
Changes in operating assets and liabilities
Accounts receivable		12,558,790			—			12,558,790
Prepaid expenses		513,363			(1,771,711	)		(1,258,348	)
Right-of-use assets – operating lease		(63,626	)		—			(63,626	)
Accounts payable		(2,935,521	)		—			(2,935,521	)
Deferred income		—			—			—
Due to related party		(2,727	)		—			(2,727	)
Accrued expense and other current liabilities		3,384,573			—			3,384,573
Net cash provided by operating activities		3,758,584			(1,771,711	)		1,986,873

Cash flows from investing activities:
Proceeds from the sale of equipment		—			—			—
Purchases of equipment		(10,943,657	)		—			(10,943,657	)
Net cash used in investing activities		(10,943,657	)		—			(10,943,657	)

Cash flows from financing activities:
Proceeds from Business Combination, net of transaction costs		34,340,225			—			34,340,225
Proceeds from issuance of notes payable		—			2,840,619			2,840,619
Payments of notes payable		(24,143	)		(1,068,908	)		(1,093,051	)
Principal payments on finance leases		(203,124	)		—			(203,124	)
Proceeds from exercise of stock options		6,750			—			6,750
Net cash provided by financing activities		34,119,708			1,771,711			35,891,419

Net increase in cash, cash equivalents, and restricted cash		26,934,635			—			26,934,635
Cash, cash equivalents, and restricted cash
Beginning of year		12,610,383			—			12,610,383
End of year	$	39,545,018		$	—		$	39,545,018

A summary of the significant accounting policies applied in preparation of the accompanying consolidated financial statements is set forth below.

Basis of Accounting, Policy [Policy Text Block]

Basis of presentation

The financial statements have been prepared in conformity with U.S. Generally Accepted Accounting Principles ("GAAP") and include all adjustments necessary for the fair presentation of the Company’s financial position for the years presented.

The Business Combination was accounted for as a reverse recapitalization in accordance with U.S. GAAP (the “Reverse Recapitalization”). Under this method of accounting, BCYP is treated as the “acquired” company and SAB Biotherapeutics is treated as the acquirer for financial reporting purposes. Accordingly, for accounting purposes, the Reverse Recapitalization was treated as the equivalent of SAB Biotherapeutics issuing stock for the net assets of BCYP, accompanied by a recapitalization. The net assets of BCYP are stated at historical cost, with no goodwill or other intangible assets recorded. SAB Biotherapeutics was determined to be the accounting acquirer based on the following predominant factors:

●

SAB Biotherapeutics’ shareholders have the largest portion of voting rights in the Company

●

the Board and Management are primarily composed of individuals associated with SAB Biotherapeutics;

●

the operations of SAB comprise the ongoing operations of the Company.

The consolidated assets, liabilities and results of operations prior to the Reverse Recapitalization are those of SAB Biotherapeutics. At the Closing Date, and subject to the terms and conditions of the Merger Agreement, each share of SAB Biotherapeutics common stock, par value $0.0001 per share, and each share of the SAB Biotherapeutics convertible preferred stock that was convertible into a share of SAB Biotherapeutics common stock at a one-to- one ratio, was converted into Common Stock equal to 0.4653 (the "Exchange Ratio"). The shares and corresponding capital amounts and losses per share, prior to the Business Combination, have been retroactively restated based on shares reflecting the Exchange Ratio established in the Business Combination.

Emerging Growth Company Status [Policy Text Block]

Emerging growth company status

The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

Further, Section 102(b)( 1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.

Consolidation, Policy [Policy Text Block]

Principles of consolidation

The accompanying consolidated financial statements include the results of the Company and its wholly owned subsidiaries, SAB Capra, LLC and Aurochs, LLC. Intercompany balances and transactions have been eliminated in consolidation.

Significant Risks Andy Uncertainties [Policy Text Block]

Significant risks and uncertainties

The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to, the results of research and development efforts, clinical trial activities of the Company’s product candidates, the Company’s ability to obtain regulatory approval to market its product candidates, competition from products manufactured and sold or being developed by other companies, and the Company’s ability to raise capital.

The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and obtaining and protecting intellectual property.

Funding from government grants is not guaranteed to cover all costs, and additional funding may be needed to cover operational costs as the Company moves forward to with our efforts to develop a commercially approved product.

Use of Estimates, Policy [Policy Text Block]

Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in the financial statements. The Company has used significant estimates in its determination of stock-based compensation assumptions, determination of the fair value of the Company’s common stock, determination of the fair value of the Private Placement Warrant liabilities, determination of the incremental borrowing rate (“IBR”) used in the calculation of the Company’s right of use assets and lease liabilities, and the valuation allowance on deferred tax assets. Actual amounts realized may differ from these estimates.

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]

Cash, cash equivalents, and restricted cash

Cash equivalents include short-term, highly liquid instruments, consisting of money market accounts and short-term investments with original maturities at the date of purchase of 90 days or less.

Amounts held in escrow by the Company pursuant to the Forward Share Purchase Agreement were reported as restricted cash on the consolidated balance sheet as of December 31, 2021.

The reconciliation of cash, cash equivalents, and restricted cash as of the years ended December 31, 2021 and 2020 was as follows:

	*December 31, 2021*		*December 31, 2020*
Cash and cash equivalents	$	33,206,712	$	12,610,383
Restricted cash		6,338,306		—
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$	39,545,018	$	12,610,383

Accounts Receivable [Policy Text Block]

Accounts receivable

Accounts receivable are carried at original invoice amount, less an allowance for doubtful accounts. The Company estimates an allowance for doubtful accounts for potential credit losses that are expected to be incurred, based on management’s assessment of the collectability of specific accounts, the aging of the accounts receivable, historical information and other currently available evidence. Receivables are written off when deemed uncollectible. To date, no receivables have been written off. The Company had no allowance for doubtful accounts as of December 31, 2021 and 2020.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of credit risk

The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to credit risk is reduced by placing such deposits in high credit quality federally insured financial institutions.

The Company received 100% and approximately 96% of its total revenue through grants from government organizations during the years ended December 31, 2021 and 2020, respectively, and 0% and approximately 4% of its total revenue through a grant from a non-government organization during the years ended December 31, 2021 and 2020, respectively.

Lessee, Leases [Policy Text Block]

Lease liabilities and right-of-use assets

The Company is party to certain contractual arrangements for equipment, lab space, and an animal facility, which meet the definition of leases under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 842, Leases (“ASC 842”). In accordance with ASC 842, the Company recorded right-of-use assets and related lease liabilities for the present value of the lease payments over the lease terms. The Company’s IBR was used in the calculation of its right-of-use assets and lease liabilities.

Research and Development Expense, Policy [Policy Text Block]

Research and development expenses

Expenses incurred in connection with research and development activities are expensed as incurred. These include licensing fees to use certain technology in the Company’s research and development projects, fees paid to consultants and various entities that perform certain research and testing on behalf of the Company, and expenses related to salaries, benefits, and stock-based compensation granted to employees in research and development functions.

During the years ended December 31, 2021 and 2020, the Company had contracts with multiple contract research organizations (“CRO”) to complete studies as part of research grant agreements. In the case of SAB- 185, the CRO has been contracted and paid by the US government. For SAB- 176, PPD Development, LP acting as the CRO oversaw the Phase 1 safety study. The terms of that agreement are subject to confidentiality, and the status of the agreement is that it is current, in good standing and approximately 90% of the contract has been paid as of December 31, 2021. SAB has also contracted with hVIVO Services Limited to conduct the Phase 2a influenza study on SAB- 176. The terms of that agreement are subject to confidentiality, and the status of the agreement is that it is current, in good standing and approximately 90% of the contract has been paid as of December 31, 2021.

Property, Plant and Equipment, Policy [Policy Text Block]

Equipment

The Company records equipment at cost less depreciation. Depreciation is calculated using straight-line methods over the following estimated useful lives:

(in years)
Animal facility equipment		7
Laboratory equipment		7
Leasehold improvements	Shorter of asset life or lease term
Office furniture & equipment		5
Vehicles		5

Repairs and maintenance expenses are expensed as incurred.

Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]

Impairment of long-lived assets

The Company reviews the recoverability of long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset may not be recoverable. If necessary, the Company compares the estimated undiscounted future net cash flows to the related asset’s carrying value to determine whether there has been an impairment. If an asset is considered impaired, the asset is written down to fair value, which is based either on discounted cash flows or appraised values in the period the impairment becomes known. The Company believes that long-lived assets are recoverable, and no impairment was deemed necessary, during the years ended December 31, 2021 and 2020.

Share-Based Payment Arrangement [Policy Text Block]

Stock-based compensation

FASB ASC Topic 718, Compensation – Stock Compensation, prescribes accounting and reporting standards for all share-based payment transactions in which employee and non-employee services are acquired. The Company recognizes compensation cost relating to stock-based payment transactions using a fair-value measurement method, which requires all stock-based payments to employees, directors, and non-employee consultants, including grants of stock options, to be recognized in operating results as compensation expense based on fair value over the requisite service period of the awards. Prior to the Business Combination, the grant date fair value of the Company's common stock was typically be determined by the Company's board of directors with the assistance of management and a third-party valuation specialist.

Subsequent to the Business Combination, the board of directors elected to determine the fair value of our post-merger common stock based on the closing market price at closing on the date of grant. In determining the fair value of stock-based awards, the Company utilizes the Black-Scholes option-pricing model, which uses both historical and current market data to estimate fair value. The Black-Scholes option-pricing model incorporates various assumptions, such as the value of the underlying common stock, the risk-free interest rate, expected volatility, expected dividend yield and expected life of the options. For awards with performance-based vesting criteria, the Company estimates the probability of achievement of the performance criteria and recognizes compensation expense related to those awards expected to vest. No awards may have a term in excess of ten years. Forfeitures are recorded when they occur. Stock-based compensation expense is classified in the consolidated statements of operations based on the function to which the related services are provided. The company recognizes stock-based compensation expense over the expected term.

Income Tax, Policy [Policy Text Block]

Income taxes

Deferred income taxes reflect future tax effects of temporary differences between the tax and financial reporting basis of the Company’s assets and liabilities measured using enacted tax laws and statutory tax rates applicable to the periods when the temporary differences will affect taxable income. When necessary, deferred tax assets are reduced by a valuation allowance, to reflect realizable value, and all deferred tax balances are reported as long-term on the consolidated balance sheet. Accruals are maintained for uncertain tax positions, as necessary.

The Company uses a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken, or expected to be taken, in a tax return. The Company has elected to treat interest and penalties related to income taxes, to the extent they arise, as a component of income taxes.

Revenue from Contract with Customer [Policy Text Block]

Revenue recognition

The Company’s revenue is primarily generated through grants from government and other (non-government) organizations.

Grant revenue is recognized during the period that the research and development services occur, as qualifying expenses are incurred or conditions of the grants are met. The Company concluded that payments received under these grants represent conditional, nonreciprocal contributions, as described in ASC 958, Not-for-Profit Entities, and that the grants are not within the scope of ASC 606, Revenue from Contracts with Customers, as the organizations providing the grants do not meet the definition of a customer. Expenses for grants are tracked by using a project code specific to the grant, and the employees also track hours worked by using the project code.

Comprehensive Income (Loss) Policy [Policy Text Block]

Comprehensive income (loss)

The Company had no items of comprehensive income (loss) other than its net income (loss).

Litigation Policy [Policy Text Block]

Litigation

From time to time, the Company is involved in legal proceedings, investigations and claims generally incidental to its normal business activities. In accordance with U.S. GAAP, the Company accrues for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Legal costs in connection with loss contingencies are expensed as incurred.

Earnings Per Share, Policy [Policy Text Block]

Earnings per share

On the Closing Date, the Company completed the Business Combination with BCYP, whereby the Company received 36,465,343 shares in exchange for all of its share capital. The effect of the Business Combination was reflected retroactively to January 1, 2020 and will be utilized for the calculation of earnings per share in all prior periods. The per share amounts have been updated to show the effect of the Exchange Ratio on earnings per share as if the exchange occurred at the beginning of both years for the consolidated financial statements of the Company. The impact of the stock exchange is also shown on the Company’s statements of changes in redeemable preferred stock and stockholders' equity (deficit).

In accordance with ASC 260, Earnings per Share (“ASC 260”), basic net income (loss) per share attributable to common stockholders is computed by dividing net income (loss) attributable to common stockholders by the weighted-average number of common stock outstanding during the period. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted-average number of common stock outstanding for the period including potential dilutive common shares such as stock options.

Segment Reporting, Policy [Policy Text Block]

Segment reporting

In accordance with ASC 280, Segment Reporting, the Company’s business activities are organized into one reportable segment, as only the Company’s operating results in their entirety are regularly reviewed by the Company’s chief operating decision maker to make decisions about resources to be allocated and to assess performance.

Common Stock Valuation [Policy Text Block]

Common stock valuations

Prior to the Business Combination, the Company was required to periodically estimate the fair value of its common stock with the assistance of an independent third-party valuation firm, as discussed above, when issuing stock options and computing estimated stock-based compensation expense. The assumptions underlying these valuations represented the Company's best estimates, which involved inherent uncertainties and the application of significant levels of judgment. In order to determine the fair value of its common stock, the Company considered, among other items, previous transactions involving the sale of our securities, our business, financial condition and results of operations, economic and industry trends, the market performance of comparable publicly traded companies, and the lack of marketability of our common stock.

Subsequent to the Business Combination, the Company now determines the fair value of common stock based on the closing market price at closing on the date of grant.

Compensation expense related to stock-based transactions is measured and recognized in the financial statements at fair value of the post-merger common stock based on the closing market price at closing on the date of grant. Stock-based compensation expense is measured at the grant date based on the fair value of the equity award and is recognized as expense over the requisite service period, which is generally the vesting period, on the straight-line method. The Company estimates the fair value of each stock option award on the date of grant using the Black-Scholes option-pricing model. Determining the fair value of stock option awards at the grant date requires judgment, including estimating the expected volatility, expected term, risk-free interest rate, and expected dividends.

Note 4 - Reverse Recapitalization and Business Combination - Schedule of Common Stock Outstanding (Details) - Big Cypress Acquisition Corp [Member]	Oct. 22, 2021 shares
Common stock, reedeemable and outstanding prior to Business Combination (in shares)	11,500,000
Less: redemption of BCYP shares (in shares)	(8,030,289)
Common stock of BCYP (in shares)	3,469,711
BCYP Founder and private shares (in shares)	3,292,200
Shares issued for services (in shares)	247,525
Total BCYP shares (in shares)	7,009,436
SAB Biotherapeutics, Inc and subsidiaries shareholders (in shares)	36,465,343
Total shares of common stock immediately after Business Combination (in shares)	43,474,779

Note 13 - Fair Value Measurements - Schedule of Fair Value Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value, Recurring [Member]	Dec. 31, 2021 USD ($)
Warrants, value	$ 10,720,130
Fair Value, Inputs, Level 1 [Member]
Warrants, value	10,292,500
Fair Value, Inputs, Level 2 [Member]
Warrants, value	0
Fair Value, Inputs, Level 3 [Member]
Warrants, value	427,630
Public Warrants [Member]
Warrants, value	10,292,500
Public Warrants [Member] \| Fair Value, Inputs, Level 1 [Member]
Warrants, value	10,292,500
Public Warrants [Member] \| Fair Value, Inputs, Level 2 [Member]
Warrants, value	0
Public Warrants [Member] \| Fair Value, Inputs, Level 3 [Member]
Warrants, value	0
Private Placement Warrants [Member]
Warrants, value	427,630
Private Placement Warrants [Member] \| Fair Value, Inputs, Level 1 [Member]
Warrants, value	0
Private Placement Warrants [Member] \| Fair Value, Inputs, Level 2 [Member]
Warrants, value	0
Private Placement Warrants [Member] \| Fair Value, Inputs, Level 3 [Member]
Warrants, value	$ 427,630

Note 13 - Fair Value Measurements

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Text Block]

(13) Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques that would be used to measure fair value into one of three levels:

	Level 1:	Unadjusted quoted prices in active markets for identical assets or liabilities.
	Level 2:	Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
	Level 3:	Unobservable inputs that reflect the reporting entity’s own assumptions.

The following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis at December 31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:

	*Total*		*Quoted Prices In Active Markets (Level 1)*		*Significant Other Observable Inputs (Level 2)*		*Significant Other Unobservable Inputs (Level 3)*
Liabilities:
Public Warrant liability	$	10,292,500	$	10,292,500	$	—	$	—
Private Placement Warrant liability	$	427,630		—		—		427,630
Total	$	10,720,130	$	10,292,500	$	—	$	427,630

Public Warrants

Each whole Public Warrant entitles the holder to purchase one share of the Company's common stock at a price of $11.50 per share, subject to adjustment as discussed herein. The Public Warrants became exercisable 30 days after the Closing Date of the Business Combination, and will expire five years after the Closing Date of the Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.

Once the warrants become exercisable, the Company may call the warrants for redemption:

	●	in whole and not in part;
	●	at a price of $0.01 per warrant;
	●	upon not less than 30 days’ prior written notice of redemption (the “30-day redemption period”) to each warrant holder; and
	●	if, and only if, the reported last sale price of the common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a
	●	30-trading day period ending three business days before the Company send the notice of redemption to the warrant holders.

If the Company calls the warrants for redemption as described above, the management will have the option to require any holder that wishes to exercise its warrant to do so on a “cashless basis.” If the management takes advantage of this option, all holders of warrants would pay the exercise price by surrendering their warrants for that number of shares of common stock equal to the quotient obtained by dividing ( x) the product of the number of shares of common stock underlying the warrants, multiplied by the excess of the “fair market value” (defined below) over the exercise price of the warrants by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants.

As of December 31, 2021, 5,750,000 Public Warrants were outstanding.

Private Placement Warrants

The Private Placement Warrants and the common stock issuable upon the exercise of the Private Placement Warrants were not transferable, assignable or saleable until after the completion of the Company's Business Combination. Additionally, the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

As of December 31, 2021, 208,600 Private Placement Warrants were outstanding.

Presentation and Valuation of the Warrants

The Warrants (both the Public Warrants and Private Placement Warrants) are accounted for as liabilities in accordance with ASC 815- 40, Derivatives and Hedging— Contracts in Entity’ s Own Equity and were presented within warrant liabilities on the consolidated balance sheet as of December 31, 2021. The initial fair value of the warrant liabilities were measured at fair value at the Closing Date, and changes in the fair value of the warrant liabilities were presented within changes in fair value of warrant liabilities in the consolidated statement of operations for the year ended December 31, 2021.

On the Closing Date, the Company established the fair value of the Private Placement Warrants utilizing both the Black-Scholes Merton formula and a Monte Carlo Simulation (“MCS”) analysis. Specifically, the Company considered an MCS to derive the implied volatility in the publicly-listed price of the Public Warrants. The Company then considered this implied volatility in selecting the volatility for the application of a Black-Scholes Merton model for the Private Placement Warrants. The Company determined the fair value of the Public Warrants by reference to the quoted market price.

The Public Warrants were classified as a Level 1 fair value measurement, due to the use of the quoted market price, and the Private Placement Warrants held privately by Big Cypress Holdings LLC, a Delaware limited liability company which acted as the Company’s sponsor in connection with the IPO (the "Sponsor"), were classified as a Level 3 fair value measurement, due to the use of unobservable inputs.

The following table provides a summary of the changes in our Level 3 fair value measurements:

	*2021*
Balance, December 31, 2020	$	—
Initial measurement on the Closing Date		244,062
Change in fair value of Private Placement Warrant liability		183,568
Balance, December 31, 2021	$	427,630

The initial measurement on the Closing Date for the Public Warrant liability was approximately $6.3 million and the change in fair value of the Public Warrant liability was approximately $4.0 million for the year ended December 31, 2021.

The key inputs into the valuations as of the Closing Date and December 31, 2021 were as follows:

	*(Initial Measurement) October 22, 2021*			*December 31, 2021*
Risk-free interest rate		1.22	%		1.24	%
Expected term remaining (years)		5.00			4.81
Implied volatility		25.5	%		43.0	%
Closing common stock price on the measurement date	$	8.44		$	7.81

As of December 31, 2021 and 2020, the Company did not have any other assets or liabilities that are recorded at fair value on a recurring basis.

The Company believes that the carrying amounts of its cash and cash equivalents, accounts receivable, and notes payable approximate their fair values due to their near-term maturities.